

An update on non-invasive urine diagnostics for human-infecting parasitic helminths: what more could be done and how?

Review

Cite this article: Archer J, LaCourse JE, Webster BL, Stothard JRussell (2020). An update on non-invasive urine diagnostics for human-infecting parasitic helminths: what more could be done and how? *Parasitology* **147**, 873–888. <https://doi.org/10.1017/S0031182019001732>





Received: 18 October 2019
Revised: 3 December 2019
Accepted: 3 December 2019
First published online: 13 December 2019

Key words:

Helminth diagnosis; helminthiasis; non-invasive urine sampling; urine diagnostics

Author for correspondence:

John Archer, E-mail: j.archer@nhm.ac.uk

John Archer^{1,2} , James E. LaCourse² , Bonnie L. Webster¹ 
and J. Russell. Stothard² 

¹Wolfson Wellcome Biomedical Laboratories, Department of Zoology, Natural History Museum, Cromwell Road, London SW7 5BD, UK and ²Department of Tropical Disease Biology, Liverpool School of Tropical Medicine, Pembroke Place, Liverpool L3 5QA, UK.

Abstract

Reliable diagnosis of human helminth infection(s) is essential for ongoing disease surveillance and disease elimination. Current WHO-recommended diagnostic assays are unreliable in low-endemic near-elimination settings and typically involve the invasive, onerous and potentially hazardous sampling of bodily fluids such as stool and blood, as well as tissue *via* biopsy. In contrast, diagnosis by use of non-invasive urine sampling is generally painless, more convenient and low risk. It negates the need for specialist staff, can usually be obtained immediately upon request and is better accepted by patients. In some instances, urine-based diagnostic assays have also been shown to provide a more reliable diagnosis of infection when compared to traditional methods that require alternative and more invasive bodily samples, particularly in low-endemicity settings. Given these relative benefits, we identify and review current research literature to evaluate whether non-invasive urine sampling is currently exploited to its full potential in the development of diagnostic tools for human helminthiasis. Though further development, assessment and validation are needed before their routine use in control programmes, low-cost, rapid and reliable assays capable of detecting transrenal helminth-derived antigens and cell-free DNA show excellent promise for future use at the point-of-care in high-, medium- and even low-endemicity elimination settings.

Introduction

Parasitic worms, often referred to as helminths, form the most common human infectious parasites in low- and middle-income countries (LMICs), causing a global burden of disease exceeding that of both malaria and tuberculosis (Hotez *et al.*, 2008; Lustigman *et al.*, 2012). The rapid, straightforward and reliable diagnosis of helminthiasis is essential for ongoing disease surveillance and successful disease control, particularly as control programmes advance towards disease elimination within endemic areas (Fig. 1), (Bergquist *et al.*, 2009; Gordon *et al.*, 2011; McCarthy *et al.*, 2012; Rollinson *et al.*, 2013; Werkman *et al.*, 2018).

Current ‘gold standard’ diagnostic assays for the majority of these diseases typically involve the invasive and cumbersome sampling of bodily fluids such as stool and blood, as well as tissue *via* biopsy (Table 1), (WHO, 2012). Not only are these procedures often painful, onerous and carry a risk of infection (with, for example, HIV), but they also require specific equipment and specialist health workers seldom available in endemic areas. A reliable assessment of disease prevalence within a given community can therefore often prove challenging as a result of patient aversions to being assessed, as well as through a lack of resources (Itoh *et al.*, 2011). Although widely considered low-cost, when taking into consideration the cumulative costs of equipment, number of personnel needed and remuneration of specialist staff, the true costs of gold standard assays are also being realized now and may likely be far more expensive than previously assumed (Turner *et al.*, 2017). In addition, whilst these techniques may be sufficiently sensitive to confirm or refute individual infection status in areas of high disease endemicity or when assessing patients burdened with a high degree of infection, in areas of low-endemicity, for example during control programme near-elimination settings, sensitivity of these techniques can seriously wane (Appendix Fig. A1), (Bergquist *et al.*, 2009; Klepac *et al.*, 2013; Hawkins *et al.*, 2016).

In contrast, diagnosis by use of non-invasive urine sampling is generally painless, more convenient, less expensive and low risk. It negates the need for specialist staff, can usually be obtained immediately upon request and is better accepted by patients (Castillo *et al.*, 2009). Further to these clear practical advantages, some urine-based diagnostic assays have also been shown to provide a more sensitive diagnosis of infection when compared to traditional methods that require alternative and more invasive bodily samples, particularly in low-endemicity settings (Sousa-Figueiredo *et al.*, 2013; Adriko *et al.*, 2014). Given these relative benefits in ease of collection, greater patient acceptability and possible improved diagnostic performance, the following review aims to evaluate whether urine is currently being exploited

© Cambridge University Press 2019. This is an Open Access article, distributed under the terms of the Creative Commons Attribution licence (<http://creativecommons.org/licenses/by/4.0/>), which permits unrestricted re-use, distribution, and reproduction in any medium, provided the original work is properly cited.




Fig. 1. Schematic outlining changes in diagnostic priorities as control programmes progress (adapted from Bergquist et al., 2009).

to its full potential with regards to the diagnosis of the major human helminth infections and highlight future research needed to further advance helminth urine-diagnostics.

Literature search strategy

A systematic online literature search was conducted, beginning in October of 2018 and ending in October of 2019. The PubMed, Cochrane Library, Google Scholar and Web of Science databases were used, following stipulated database guidelines, to search for any literature published between 1919 and 2019 within peer-reviewed journals relevant to inputted search terms (National Center for Biotechnology Information., 2019; Cochrane Library., 2019; Google Scholar., 2019; Web of Science., 2019).

Three focal search terms, ‘diagnosis’, ‘diagnostic’ and ‘detection’, were used in conjunction with either disease name(s) (e.g. ‘schistosomiasis’, ‘Bilharzia’ and ‘snail fever’ or ‘lymphatic filariasis’ and ‘elephantiasis’), or pathogen species (e.g. ‘*Schistosoma haematobium*’ or ‘*Wuchereria bancrofti*’) and ‘urine’ or ‘transrenal’. Following this initial search, additional terms were included, such as diagnostic marker (e.g. ‘antigen’) and/or assay method (e.g. ‘enzyme-linked immunosorbent assay’), to potentially uncover additional literature. The abstracts of all publication hits were read and assessed for their relevance to review. Irrelevant articles were not included in the review, whereas all relevant articles were read in full. Publications deemed relevant were those that highlighted any primary research concerning the detection of any human-infecting parasitic helminth outlined in Table 1, or closely related non-human animal-infecting species, within urine samples taken from humans or non-human animals. Any secondary research, for example, systematic reviews or meta-analyses that met these criteria were also included. All literature cited within relevant articles was also screened, again to potentially uncover additional literature not provided by initial database searches.

Macroscopic changes to urine as a means of diagnosing urogenital schistosomiasis

Visible haematuria is often indicative of active urogenital schistosomiasis, caused by infection with *Schistosoma haematobium*

(Colley et al., 2014). As such, cost-effective questionnaires involving either the self-reporting of blood in the urine by patients or the observation of blood in the urine by health workers have been used in an attempt to rapidly identify infected individuals and disease prevalence within endemic areas (Lengeler et al., 2002a,b; Okeke and Ubachukwu, 2014; Atalabi et al., 2017).

The sensitivity of self-reporting the presence of blood in the urine for diagnosis of *S. haematobium* infection has been extensively assessed (Bogoch et al., 2012; Bassiouny et al., 2014). Comparing patient questionnaire responses to the diagnostic gold standard (identification of ova in concentrated urine samples via microscopy), it has been concluded that despite the method’s practical advantages and relatively low cost, self-reported macrohaematuria alone is unreliable at the individual level primarily because visible haematuria typically only presents in individuals burdened with particularly heavy infections (Bogoch et al., 2012). In addition, macrohaematuria is also often a symptom of common urinary tract infections and bladder stones (Appendix Fig. A1), (Le and Hsieh, 2017). It has also been highlighted that the self-reporting of blood in the urine by school-aged children, the demographic customarily selected for helminth surveillance within a given community, can be unreliable due to either a young girl’s reluctance to admit the onset of menses, or a young boy’s eagerness to proclaim his ‘coming of age’ as a result of gross haematuria often being considered a natural sign of the onset of puberty (Montresor et al., 2002; Colley et al., 2014).

For these reasons, the diagnostic reliability of having trained and experienced personnel to identify the presence of macroscopic blood in the urine has also been assessed, again, comparing the method to urine-egg detection by microscopy (Okeke and Ubachukwu, 2014). Once more it was concluded that, unless used in conjunction with more taxing and costly methods, macrohaematuria does not provide adequate sensitivity when compared to egg microscopy, and in using only this method low-, or even moderate-intensity, infections would likely be missed.

It is generally accepted that although a useful and easily implemented tool in initial baseline observations to confirm *S. haematobium* presence in highly-endemic populations, in areas of low-endemicity, or when evaluating programmatic intervention

Table 1. WHO-recommended diagnostic techniques for major human helminth infections and how technique invasiveness compares to that of urine sampling.

Disease (also known as)	Infectious agent (helminth species)	WHO-recommended diagnostic technique (WHO, 2012)	Degree of sample invasiveness relative to urine sampling*
Urogenital Schistosomiasis (Bilharzia/Snail Fever)	<i>Schistosoma haematobium</i>	Identification of ova in concentrated urine sample <i>via</i> microscopy	±
Ascariasis (Roundworm)	<i>Ascaris lumbricoides</i>	Identification of ova in concentrated faecal smear <i>via</i> microscopy	+
Trichuriasis (Whipworm)	<i>Trichuris trichiura</i>		+
Hookworm Infection	<i>Ancylostoma duodenale</i>		+
	<i>Necator americanus</i>		+
Gastrointestinal Schistosomiasis (Bilharzia/Snail Fever)	<i>Schistosoma mansoni</i>		+
	<i>Schistosoma japonicum</i>		+
	<i>Schistosoma mekongi</i>		+
	<i>Schistosoma guineensis</i>		+
	<i>Schistosoma intercalatum</i>		+
Liver Fluke Infection	<i>Fasciola hepatica</i>		+
	<i>Fasciola gigantica</i>		+
	<i>Opisthorchis viverrini</i>		+
Taeniasis (Tapeworm infection)	<i>Taenia solium</i> (adult stage)		+
	<i>Taenia saginata</i> (adult stage)		+
Strongyloidiasis (Threadworm infection)	<i>Strongyloides stercoralis</i>	Identification of larvae in concentrated faecal smear <i>via</i> microscopy	+
Lymphatic Filariasis (Elephantiasis)	<i>Wuchereria bancrofti</i>	Identification of microfilariae in blood smear (taken to coincide with blood-circulating periodicity behaviour) <i>via</i> microscopy	++
	<i>Brugia malayi</i>		++
	<i>Brugia timori</i>		++
Loiasis (Loa)	<i>Loa loa</i>	Identification of microfilariae in blood smear <i>via</i> microscopy	++
Cysticercosis/neurocysticercosis	<i>Taenia solium</i> (larval cysts)	MRI or CT brain scan	++
Onchocerciasis (River Blindness)	<i>Onchocerca volvulus</i>	Identification of microfilariae in multiple skin snips <i>via</i> microscopy	+++

*Positive/negative symbols denote degree of increase in sample invasiveness when compared to urine sampling where: '±' indicates relative comparable invasiveness; '+' indicates a moderate increase in sample invasiveness; '++' indicates a considerable increase in sample invasiveness and; '+++ indicates a major increase in sample invasiveness.

success in reducing disease prevalence and transmission, alternative and more accurate diagnostic approaches should be used (Utzinger *et al.*, 2015; Mutapi *et al.*, 2017).

Microscopic changes to urine as a means of diagnosing urogenital schistosomiasis

The current gold standard of *S. haematobium* diagnosis involves the filtering, staining and observation of morphologically distinct eggs excreted in urine (Le and Hsieh, 2017). Using a syringe and polycarbonate filters with a pore size of 8–30 µm, eggs from 10 mL of a well-shaken urine sample can be isolated, stained and examined under a microscope (Peters *et al.*, 1976; Colley *et al.*, 2014; Utzinger *et al.*, 2015). This has long been the preferred method of *S. haematobium* diagnosis as it allows for a straightforward and reasonably inexpensive means of confirming infection within an individual or presence within a community (through sample pooling), using relatively unsophisticated and somewhat field-appropriate equipment. Additionally, and importantly, eggs

can be quantified; providing a moderately accurate assessment of infection intensity within an individual that can then be used to estimate the degree of clinical morbidity (Colley *et al.*, 2014; Utzinger *et al.*, 2015; Corstjens *et al.*, 2017).

The many shortcomings of urine-egg microscopy, however, are well understood (Braun-Munzinger and Southgate, 1992; Le and Hsieh, 2017; Ajibola *et al.*, 2018). Owing to heterogeneities in egg output occurring between different periods of the same day, between different days and even between different seasons, accurate diagnosis and morbidity assessment of any given individual using just one urine sample is unlikely (Braun-Munzinger and Southgate, 1992; Le and Hsieh, 2017; Christensen *et al.*, 2018). To mitigate this, multiple urine samples from the same individual can be taken over consecutive days, ideally between the hours of 10:00am and 2:00pm to coincide with optimum egg passage (Le and Hsieh, 2017). Repeated bouts of urine filtration and microscopy is, however, taxing work; a reasonable balance between diagnostic accuracy, time spent and financial cost must be met and even then, overt improvements in diagnostic

sensitivity are rarely seen (Stothard *et al.*, 2014). Differences in diagnostic sensitivity between more and lesser-experienced technicians are also often found, further complicating matters when large quantities of urine samples require assessment (Knopp *et al.*, 2015).

Of more urgent concern is urine-egg microscopy's poor sensitivity when used in areas of low- or even moderate-prevalence settings (WHO, 2013; Le and Hsieh, 2017). As egg output declines, the sensitivity of urine-egg microscopy is significantly reduced resulting in a variety of challenges beyond just reliably identifying individuals burdened with low-intensity infections. Some of these challenges include accurately estimating clinical morbidity, evaluating the impact of programmatic interventions, diagnosing preschool aged children and assessing new diagnostic tools (Stete *et al.*, 2012; Knopp *et al.*, 2013, 2018; Le and Hsieh, 2017). Recent concern has also been raised about urine-egg microscopy's poor sensitivity when attempting to detect 'ultra-light' infections, regarded as those that result in the expulsion of between only one and five eggs per 10 mL of urine (Knopp *et al.*, 2018). Given the reproductive biology of schistosomes, just one infected individual excreting such minute numbers of eggs that may go on to infect and asexually reproduce within the appropriate intermediate freshwater snail host, potentially producing hundreds of cercariae per day, can cause the re-infection of an entire community (Colley *et al.*, 2014). As such, in elimination settings or where treatment is targeted only to infected individuals that may be tracked, reassessed and retreated, any infected individuals must be quickly identified to ensure prompt treatment and total interruption of transmission; highlighting the urgent need for rapid, simple-to-use diagnostic tools deployable at the point-of-care (POC) and able to detect ultra-light infections (Hawkins *et al.*, 2016; Knopp *et al.*, 2018).

Although macrohaematuria is typically present only in those harbouring heavy *S. haematobium* infections, microhaematuria, i.e. trace amounts of blood in the urine not visible to the naked-eye, can occur even in moderate- and low-intensity infections and can be detected using rapid, simple-to-use and relatively inexpensive reagent-strips that can be used at the point-of-care (Ochodo *et al.*, 2015; Le and Hsieh, 2017; Knopp *et al.*, 2018).

The accuracy of urine-heme reagent-strips, or 'dipsticks' for the indirect diagnosis of urogenital schistosomiasis have also been extensively assessed (Robinson *et al.*, 2009; Krauth *et al.*, 2015; Hassan *et al.*, 2018; Musa and Dadah, 2018; Knopp *et al.*, 2018). Recent reviews and meta-analyses have been undertaken to evaluate their diagnostic accuracy with a specific focus on high-, medium- and low-prevalence settings and in populations that have previously undergone repeated mass drug administration (MDA) treatment with praziquantel (King and Bertsch, 2013; Ochodo *et al.*, 2015). In most cases, it has been concluded that although the diagnostic performance of urine-heme dipsticks is reduced in low-transmission areas and despite a range of possible confounding reasons for the presence of blood in the urine (such as urinary tract infections, bladder stones and menstrual blood), at the population level, urine-heme dipsticks should be considered more accurate than urine-egg microscopy (Ochodo *et al.*, 2015). In addition, urine-heme dipsticks do not require specially trained microscopists, are less influenced by daily fluctuations in egg passage and take far less time to carry out (Krauth *et al.*, 2015). It has also been concluded, however, that whilst urine-heme dipsticks should continue to be used to monitor the early-stage population-level impact of schistosomiasis control programmes (i.e. when assessing the initial baseline prevalence or when evaluating changes in overall prevalence after early intervention implementation), in elimination settings, or again when treatment is targeted only to infected individuals, neither the urine-heme dipstick or urine-egg microscopy can reliably identify

individuals burdened with low- or ultra-light-intensity infections still capable of maintaining disease transmission (King and Bertsch, 2013; Ochodo *et al.*, 2015; Knopp *et al.*, 2018). Further assessment of urine-heme dipstick diagnostic performance using more sophisticated and sensitive methods such as *Schistosoma* antigen or DNA detection, rather than egg microscopy, has been encouraged (King and Bertsch, 2013).

As well as microhaematuria, leukocyturia (the abnormal presence of white blood cells in the urine) and proteinuria (the abnormal presence of proteins in the urine) may also be used as proxy to diagnose urogenital schistosomiasis, though both methods been found to be significantly less sensitive and specific than urine-heme dipsticks (Ochodo *et al.*, 2015). It has been suggested, however, that the use of urine-heme dipsticks in conjunction with low-cost and field-deployable assays capable of detecting albuminuria (urine-albumin concentrations of $>40 \text{ mg L}^{-1}$), may provide a reliable diagnosis of infection in high-endemicity settings whilst also allowing assessment of kidney and urinary tract morbidity associated with chronic disease (Rollinson *et al.*, 2005; Sousa-Figueiredo *et al.*, 2009).

Like macroscopic changes, microscopic changes to urine are also considered now insufficiently sensitive to detect *S. haematobium* infection in low-prevalence settings or within individuals harbouring low-level infections. In addition, these changes only occur as a result of infection with *S. haematobium*. In endemic areas, co-infection with multiple helminth species is commonplace, highlighting the need for multiplex assays capable of reliably detecting multiple helminth species using just one bodily sample.

Detection of anti-helminth urine-antibodies

Immunodiagnostic assays for the detection of blood-circulating anti-helminth antibodies have been used to diagnose infection with many human-infecting helminthiases (Rebollo and Bockarie, 2014; Kemal *et al.*, 2015; Vlaminck *et al.*, 2015; Akue *et al.*, 2018). Of all antibody-targeting immunological assays, the most frequently employed is some form of the enzyme-linked immunosorbent assay (ELISA), the diagnostic functionality of which relies on the highly specific antigen-antibody binding that occurs during the body's immune response to invading foreign pathogens (Lazcka *et al.*, 2007).

Due to ease of sample procurement relative to blood sampling, the diagnostic potential of targeting anti-helminth antibodies expelled within the urine using immunodiagnostic assays has also been assessed; targeting and successfully detecting urine-based antibodies formulated against a range of helminth species (Table 2). Of those studies comparing the diagnostic accuracy between targeting urine- and serum-based antibodies, all reported good association in diagnostic performance whilst no additional effort in urine-sample preparation was required, presenting a compelling argument for moving beyond invasive blood-based diagnostics (Elhag *et al.*, 2011; Nagaoka *et al.*, 2013; Eamudomkarn *et al.*, 2018).

Although highly specific even in low-endemicity settings, antibody detection using the ELISA requires sophisticated equipment, specially trained health workers and expensive reagents that require cold chain typically unavailable to those in disease-endemic regions, particularly when hoping to obtain a quantitative diagnosis that indicates degree of infection within an individual (Bergquist *et al.*, 2009; Tchuem Tchuente, 2011). As such, regardless of the bodily sample taken, these requirements make it difficult to envisage the future scale-up and field-deployment of the ELISA at the point-of-care, where the simple-to-use, rapid and sensitive diagnosis is needed. It is for this reason that much attention has been given to the

Table 2. Anti-helminth antibodies detected within urine and immunodiagnostic assay used.

Bodily habitat	Species (life stage)	Antibody detected	Assay used	References
Circulatory system	<i>S. mansoni</i> (adult stage)	IgG against soluble worm antigen (SWA)	ELISA	(Elhag <i>et al.</i> , 2011)
	<i>S. haematobium</i> (adult stage)	IgG against soluble worm antigen (SWA)	ELISA	(Elhag <i>et al.</i> , 2011)
	<i>S. haematobium</i> (ova)	IgG against <i>S. haematobium</i> soluble egg antigen (SEA)	RDT-sh	(Sheele <i>et al.</i> , 2013)
	<i>S. japonicum</i> (ova)	IgG against <i>S. japonicum</i> soluble egg antigen (SEA)	ELISA	(Itoh <i>et al.</i> , 2003a)
Lymphatic system (adult stage/L3 larval stage) and/or circulatory system (microfilariae larval stage)	<i>W. bancrofti</i> (life-stage not specified)	Urinary IgG4 against <i>Brugia pahangi</i> crude soluble antigen	Modified ELISA: high-density latex bead assay	(Nagaoka <i>et al.</i> , 2013)
			ELISA	(Itoh <i>et al.</i> , 2003b; Weerasooriya <i>et al.</i> , 2008)
		Filaria-specific IgG4	ELISA	(Rattanaxay <i>et al.</i> , 2001; Itoh <i>et al.</i> , 2007; Samad <i>et al.</i> , 2013)
Gastrointestinal tract (adult stage) and/or circulatory system (larval stage)	<i>S. stercoralis</i> (life-stage not specified)	IgG against <i>S. ratti</i> crude soluble antigen	ELISA	(Eamudomkarn <i>et al.</i> , 2018)
Liver	<i>O. viverrini</i> (adult stage)	IgG, IgA, IgG4 against <i>O. viverrini</i> crude somatic antigen	ELISA	(Sawangsoda <i>et al.</i> , 2012)
		IgG, IgG4 against <i>O. viverrini</i> crude somatic antigen	ELISA	(Tesana <i>et al.</i> , 2007)

development of simple-to-use point-of-care rapid diagnostic test (POC-RDT) devices capable of rapidly detecting blood-circulating anti-helminth antibodies (Weil *et al.*, 2000; Coulibaly *et al.*, 2013; Steel *et al.*, 2013). Further development of these for use with urine samples, however, is lacking. Two novel transrenal antibody-detecting RDTs that have been developed and assessed involve the use of antigen-coated coloured latex beads for the detection of filaria-specific IgG4 (Nagaoka *et al.*, 2013), and the filtering of urine to isolate human IgG bound to *S. haematobium* ova, both requiring significantly less equipment, reagents and technical expertise than conventional immunodiagnostic assays (Sheele *et al.*, 2013). Although promising, further evaluation for reliability, field-applicability, upscale and deployment is needed.

Another principal concern when targeting antibodies to determine infection status is the inability to distinguish between active and past infections owing to high antibody titres remaining within the body long after treatment success and infection clearance (Rollinson *et al.*, 2013; Utzinger *et al.*, 2015). This becomes particularly problematic when attempting to evaluate the impact of programmatic control strategies in areas that have undergone control intervention. As an example, individuals within areas having undergone mass administration with albendazole for the treatment of ascariasis may have indeed cleared any infection, however, any diagnostic assay targeting anti-*Ascaris* antibodies used to assess these individuals may remain positive (Jourdan *et al.*, 2018). In areas where disease elimination is sought, it has been suggested that antibody-targeting assays may be appropriate for use with young children who have not yet received treatment as a means of assessing whether the transmission is still taking place (Jourdan *et al.*, 2018; Takagi *et al.*, 2019). In doing so, seroconversion rate, typically somewhere between at least 4 and 8 weeks after initial exposure, must be taken into consideration (van Grootveld *et al.*, 2018; Vlaminck *et al.*, 2019).

Persistent post-infection circulating antibodies also cause difficulty when attempting to evaluate the true accuracy of antibody-targeting diagnostic assays; typically performed *via* comparison to gold standard assays that may themselves have poor-sensitivity. In doing this, antibody assays will consistently appear highly-sensitive with likely concurrent low positive predictive values (PPV), (Appendix Figure A1), whereas individuals testing negative by gold standard methods but positive by antibody-detecting methods may plausibly be harbouring active but low-level infections, or may indeed be currently uninfected after having cleared a previous infection (Doenhoff *et al.*, 2004).

Cross-reactivity of antibodies between different helminth genera is also an issue (Genta, 1988; Lammie *et al.*, 2004; Weerakoon *et al.*, 2015; Lamberton and Jourdan, 2015; Garcia *et al.*, 2018; Song *et al.*, 2018). In some cases, genera-, or even species-specific identification of infecting helminths is essential for safe treatment strategies, for example when providing ivermectin to treat onchocerciasis in loiasis-endemic areas (Gardon *et al.*, 1997), or for diagnosis of species-specific pathologies such as female and male genital schistosomiasis (Itoh *et al.*, 2011; Vlaminck *et al.*, 2016; Kayuni *et al.*, 2019; Kukula *et al.*, 2019). In circumstances such as these, diagnostic assays with a higher degree of specificity than that of antibody-targeting assays are needed.

Because of the technical, financial and logistical challenges presented by anti-helminth antibody detection and when considering the very limited resources available for the development and validation of novel diagnostic assays, perhaps focus is best placed elsewhere, on more user-friendly, cost-effective and reliable methods.

Detection of helminth-derived urine-antigens

Targeting urine-antigens has multiple advantages over targeting transrenal antibodies; detection of antigens indicates active

infection; diagnostic assays that target antigens can, therefore, be used to evaluate disease intervention strategies such as MDA and vector control; invading parasites may be detected soon after infection and antigen levels generally correlate well with parasite load (Corstjens *et al.*, 2014; Worasith *et al.*, 2015; Ochodo *et al.*, 2015; Kamel *et al.*, 2019; Sousa *et al.*, 2019). As with antibody detection, good association between urine- and serum-based antigen detection has been found in high-, medium- and low-endemicity settings, further strengthening the argument for moving towards non-invasive urine sampling (van Dam *et al.*, 2004; Kamel *et al.*, 2019; Sousa *et al.*, 2019).

Again, most immunodiagnostic assays used to detect helminth-derived urine-antigens, such as conventional ELISAs, are currently unsuited for point-of-care use (Table 3). At present, efforts to develop simple-to-use POC-RDTs for the detection of helminth urine-antigens have focused primarily on test devices capable of diagnosing urogenital and intestinal schistosomiasis, though a point-of-care lateral-flow dipstick to detect *O. volvulus*-derived urine-antigens has also been developed (Ayong *et al.*, 2005).

The reliability of urine-antigen POC-RDTs when used in low-endemicity settings or when assessing individuals with low-intensity infections that may give unclear 'trace' results is, however, disputed (Coelho *et al.*, 2016; Peralta and Cavalcanti, 2018). Recent meta-analyses suggest that, although more rapid and sensitive than stool-microscopy, under these circumstances' targeting the schistosome urine circulating cathodic antigen (CCA) by use of the CCA-POC-RDT is not sufficiently sensitive to reliably detect *S. mansoni* infection at the individual level (Danso-Appiah *et al.*, 2016). It has been concluded that because of their low-cost, ease of use and patient-compliance, the CCA-POC-RDT may serve as a useful tool for disease-prevalence mapping and monitoring of control programmes relevant to *S. mansoni* in high- and medium-endemicity settings. In low-endemicity settings, however, when highly sensitive diagnostics capable of detecting low-intensity infections with a range of helminth species at the individual level are required, alternative and more sensitive assays are needed.

Revisions in assay protocols can improve the sensitivity and specificity of RDTs capable of detecting schistosome-urine-antigens beyond that of even lab-based ELISA assays, even in light-infections (Coelho *et al.*, 2016; Kamel *et al.*, 2019). Recently, the development of an up-converting phosphor lateral-flow (UCP-LF) assay targeting transrenal circulating anodic antigens (CAA) has shown that diagnosis of ultra-light schistosome infections through urine-CAA detection is possible (Corstjens *et al.*, 2014; van Dam *et al.*, 2015a,b). The genus-specific assay has shown extremely high sensitivity for the detection of *S. haematobium*, *S. mansoni*, *S. japonicum* and *S. mekongi* urine-CAA, even in low-endemicity settings (Corstjens *et al.*, 2014; van Dam *et al.*, 2015a,b; Knopp *et al.*, 2015; de Dood *et al.*, 2018; Sousa *et al.*, 2019). Further to its high-specificity, the UCP-LF CAA assay offers additional advantages over urine- and stool- microscopy in that the UCP-LF CAA is much higher-throughput and that only urine sampling is required to diagnose both urogenital and intestinal schistosomiasis (Knopp *et al.*, 2015; Corstjens *et al.*, 2014). Though treatment of both forms of schistosomiasis is identical, (40 mg praziquantel per kg body weight), if using this assay in areas co-endemic for both *S. haematobium* and *S. mansoni*, additional steps would be required to diagnose species-specific infection, associated pathologies, cure rates and drug efficacies.

Although not yet fully suited for point-of-care use, the UCP-LF CAA assay requires only a reliable source of electricity, simple centrifugation facilities and pipetting capacities; offering a high-throughput and highly-sensitive means of diagnosing

schistosomiasis through urine sampling whilst requiring lesser-equipped laboratory infrastructure than conventional immuno-diagnostic assays (Knopp *et al.*, 2015; Sousa *et al.*, 2019). As the assay is also currently too expensive for commercial and routine use in schistosomiasis control programmes, efforts to develop a less expensive, rapid and simple-to-use CAA-POC-RDT that retains the UCP-LF CAA's high-sensitivity have begun (Knopp *et al.*, 2015). Until then, it has been suggested that the existing assay could be used as a robust means of confirming or refuting indecisive test results at the individual level given by alternative, less sensitive but more field-appropriate, methods (de Dood *et al.*, 2018).

Additional advancements in antigen-detecting immunodiagnostic POC-RDTs include the development of a lateral flow immunochromatographic test strip capable of detecting circulating *S. mansoni* antigen (CSA) within the urine using colloidal gold and mesoporous silica nanoparticles (Kamel *et al.*, 2019). Though currently adapted only for diagnosis of infection with *S. mansoni*, these rapid and field-applicable test strips showed extremely high sensitivity when used to assess patients burdened with light infections and were even found to provide a more sensitive diagnosis than the conventional lab-based sandwich ELISA. Further assessment and validation of these RDT test strips, as well as adaptation for detection of other helminth-species urine-antigens, is encouraged.

It should be noted that the diagnostic potential of targeting any helminth-derived antigen through urine sampling will greatly depend on whether or not that antigen is expelled in the urine. Blood-circulating antigens with a high molecular mass may be too large to pass from the glomerular capillaries into the glomerular capsule and onto the bladder, and even of those that do, some will undoubtedly degrade into smaller products not recognised by monoclonal antibodies prior to diagnosis (Chanteau *et al.*, 1994). Moreover, some helminth antigens may not be expelled in the urine because of that helminth species' bodily habitat. The adult form of *Ascaris lumbricoides* and various species of cestode, for example, reside within the gastrointestinal lumen and so do not directly interact with circulating blood (Lamberton and Jourdan, 2015).

Additionally, as with antibodies, any transrenal antigens targeted for diagnostic purposes will require assessment as to whether or not and to the degree with which they may cross-react with other antigens and/or other proteins expelled in the urine. Helminth-derived blood-circulating antigens from various genera of filarial nematode, for example, are known to cross-react in co-endemic areas; severely hampering the diagnostic efficacy of assays needed to identify infected individuals and provide safe treatment (Hertz *et al.*, 2018). In addition, the *Schistosoma* CCA assay has been found to cross-react with antigens from other parasites, general inflammatory biomarkers and even metabolites expelled in the urine of pregnant women; also hampering diagnostic efficacy (van Dam *et al.*, 1996; Utzinger *et al.*, 2016).

Detection of helminth-derived transrenal nucleic acid

Diagnosis *via* detection of helminth DNA expelled in the urine has many advantages beyond ease of sample procurement; it can be highly sensitive (trace levels of DNA can be detected), highly specific, parasite load can be quantified, assays can be high through-put and multiple species of parasitic helminth can be identified within one multiplex assay (Gordon *et al.*, 2011; Phuphisut *et al.*, 2014; Melchers *et al.*, 2014). Possible further benefits include the early detection of anthelmintic drug resistance development, the ability to monitor helminth population genetic variation over time, relatively less arduous sample preparation when compared to blood, stool or tissue samples and the

Table 3. Helminth-derived antigens detected within the urine and immunodiagnostic assay used.

Bodily habitat	Species (life stage)	Antigen detected	Assay used	References	
Circulatory system	<i>S. mansoni</i> (adult stage)	Circulating cathodic antigen (CCA)	ELISA	(Ochodo <i>et al.</i> , 2015; Peralta and Cavalcanti, 2018)	
			CCA lateral-flow strip POC-RDT	(Stothard <i>et al.</i> , 2006; Ochodo <i>et al.</i> , 2015; Peralta and Cavalcanti, 2018)	
		Circulating anodic antigen (CAA)	ELISA	(Peralta and Cavalcanti, 2018)	
			Up converted phosphor-lateral flow CAA assay	(Sousa <i>et al.</i> , 2019)	
	Circulating <i>Schistosoma mansoni</i> antigen (CSA)	Lateral-flow immunochromatographic test strip/ELISA	(Kamel <i>et al.</i> , 2019)		
		<i>S. haematobium</i> (adult stage)	Circulating cathodic antigen (CCA)	ELISA	(Stothard <i>et al.</i> , 2006; Ochodo <i>et al.</i> , 2015; Peralta and Cavalcanti, 2018)
	CCA lateral-flow strip POC-RDT			(Peralta and Cavalcanti, 2018)	
	Circulating anodic antigen (CAA)		ELISA	(Peralta and Cavalcanti, 2018)	
			Up converted phosphor-lateral flow CAA assay	(Corstjens <i>et al.</i> , 2014; Knopp <i>et al.</i> , 2015; de Dood <i>et al.</i> , 2018)	
		<i>S. japonicum</i> (adult stage)	Circulating cathodic antigen (CCA)	CCA lateral-flow strip POC-RDT	(van Dam <i>et al.</i> , 2015a,b)
Circulating anodic antigen (CAA)			Up converted phosphor-lateral flow CAA assay	(van Dam <i>et al.</i> , 2015a,b)	
<i>S. mekongi</i> (adult stage)		Circulating cathodic antigen (CCA)	CCA lateral-flow strip POC-RDT	(van Dam <i>et al.</i> , 2015a,b; Vonghachack <i>et al.</i> , 2017)	
		Circulating anodic antigen (CAA)	Up converted phosphor-lateral flow CAA assay	(van Dam <i>et al.</i> , 2015a,b; Vonghachack <i>et al.</i> , 2017)	
<i>L. loa</i> (microfilariae larval stage)		LOAG_16297 protein	Nanobore reversed-phased liquid chromatography-tandem mass spectrometry (RPLC-MS/MS)	(Drame <i>et al.</i> , 2016)	
<i>O. volvulus</i> (microfilariae larval stage)		Unspecified filarial larval antigen	POC-RDT dipstick assay	(Ayong <i>et al.</i> , 2005)	
Lymphatic system (adult stage/L3 larval stage) and/or circulatory system (microfilariae larval stage)		<i>W. bancrofti</i> (life-stage not specified)	Unspecified filarial antigen	Inhibition ELISA	(Chenthamarakshan <i>et al.</i> , 1996)
				Sandwich ELISA	(Huijun <i>et al.</i> , 1987)
	Double antibody sandwich ELISA			(Ramaprasad <i>et al.</i> , 1988)	
	Two-site immunoradiometric assay			(Henry <i>et al.</i> , 1987)	
	Counterimmuno-electrophoresis (CIEP)			(Weil <i>et al.</i> , 1986)	
	Urinary filarial antigen UFAC ₂	SDS-PAGE and immunoblotting	(Chenthamarakshan <i>et al.</i> , 1993)		
	<i>B. malayi</i> (life-stage not specified)	Unspecified filarial antigen	Sandwich ELISA	(Huijun <i>et al.</i> , 1987)	

(Continued)

Table 3. (Continued.)

Bodily habitat	Species (life stage)	Antigen detected	Assay used	References
Subcutaneous tissue	<i>O. volvulus</i> (adult stage)	Unspecified filarial antigen	Lateral-flow strip POC-RDT	(Ayong <i>et al.</i> , 2005)
Central nervous system	<i>T. solium</i> (larval stage)	Cysticercal antigen	B158/B60 Urine Ag-ELISA	(Mwape <i>et al.</i> , 2011)
		Secretory-excretory antigen	Monoclonal antibody Ag-ELISA	(Castillo <i>et al.</i> , 2009)
Liver	<i>O. viverrini</i> (adult stage)	Unspecified <i>T. solium</i> antigen	Capture ELISA	(Paredes <i>et al.</i> , 2016)
		Excretory-secretory antigen	Modified ELISA (Urine OV-ES) Assay	(Worathith <i>et al.</i> , 2015)

ability to detect pre-patent infections (Enk *et al.*, 2010, 2012; Lamberton and Jourdan, 2015; Minetti *et al.*, 2016).

Cell-Free DNA (cfDNA) has been defined as extracellular fragments of DNA found in bodily fluids or tissues, including the urine (Weerakoon *et al.*, 2015, 2018; Weerakoon and McManus, 2016). It can be detected through use of nucleic acid amplification tests (NAATs), the more common of which include conventional polymerase chain reaction (PCR), nested PCR (nPCR) and quantitative or real-time PCR (qPCR/rtPCR) (Gordon *et al.*, 2011; Verweij and Stensvold, 2014). Praised for their high sensitivity and specificity, NAATs are now becoming recognised as a more reliable means of helminth diagnosis than current gold standard and immunodiagnostic assays, particularly in low-intensity infections and even when targeting cfDNA expelled in the urine (Enk *et al.*, 2012; Ibrionke *et al.*, 2012; Melchers *et al.*, 2014; Lodh *et al.*, 2016; Krolewiecki *et al.*, 2018).

To date, using NAATs, numerous studies have evaluated the diagnostic efficacy of targeting transrenal cfDNA from helminths known to reside within a range of bodily habitats, all of which have reported higher sensitivity when compared to gold standard techniques (Table 4). Although the detectable presence of transrenal cfDNA has not yet been confirmed for all human-infecting parasitic helminths, as validated assays do currently exist for the detection of many helminth species' cfDNA in other bodily samples, adaptation of these to assess presence and diagnostic efficacy of helminth-derived cfDNA within the urine should be straightforward (Gordon *et al.*, 2011; Minetti *et al.*, 2016; Weerakoon and McManus, 2016). Of particular interest would be to determine the presence of transrenal *Onchocerca volvulus* and *Loa loa* cfDNA, given their subcutaneous and deep tissue habitats and understandable patient aversions to invasive skin-snip biopsies currently used to confirm onchocerciasis infection (Knopp *et al.*, 2012). Of additional interest would be to determine the presence of transrenal cfDNA from *Trichuris trichiura* and hookworm parasites as, despite sharing their gastrointestinal tract habitat with *Ascaris lumbricoides* and cestodes, adult forms do interact with circulating blood (Jourdan *et al.*, 2018). As with *A. lumbricoides* and cestode urine-antigen detection, detection of transrenal cfDNA from these helminths may be unlikely. Cell-free DNA from *Strongyloides stercoralis*, another gut-dwelling helminth, has been successfully detected in urine, though it is speculated this is due to tissue dissemination during larval-form autoinfection (Lodh *et al.*, 2016).

Although clearly a highly sensitive method of confirming or refuting infection, many financial, logistical and methodological challenges must be overcome if NAATs are to replace current diagnostic standards, regardless of the bodily sample taken. Perhaps of primary concern are the high costs associated with NAATs, such as PCR and qPCR, when compared to current, less costly, gold standard assays. Expensive reagents, sophisticated equipment and remuneration of specialist technical staff all contribute to overall expenditure, again resulting in a diagnostic assay likely unaffordable to most health workers in resource-poor settings (Minetti *et al.*, 2016). Another major challenge is the upscale and field-applicability of assays targeting cfDNA. In programmatic elimination settings where rapid and reliable detection of few infected individuals is crucial for disease elimination, diagnostic assays must be deployable at the point-of-care. Not only are conventional NAATs themselves currently unsuited for point-of-care use, but essential sample preparation steps, such as DNA extraction, that also require specific laboratory equipment and reagents, prevent the use of conventional NAATs anywhere lacking sophisticated laboratory infrastructure. In addition, to what extent helminth-derived cfDNA continues to be expelled in the urine after infection clearance is largely unknown and likely varies between parasite species' bodily habitat and degree of the previous infection.

Table 4. Helminth cfDNA detected within the urine and nucleic acid amplification test (NAAT) used.

Bodily habitat	Species	Antigen detected	Assay used	References
Circulatory System	<i>S. haematobium</i>	121 bp repeat fragment <i>Dra1</i>	PCR	(Shiff <i>et al.</i> , 2011; Ibrionke <i>et al.</i> , 2012; Lodh <i>et al.</i> , 2014)
			RPA	(Rostron <i>et al.</i> , 2019)
		rDNA internal transcribed spacer (ITS) region	PCR	(Sandoval <i>et al.</i> , 2006)
		77 bp fragment of internal transcribed spacer-2 (ITS2) sub-unit	PCR	(Aryeetey <i>et al.</i> , 2013)
		Fragments of small subunit SSU rRNA	LAMP	(Bayoumi <i>et al.</i> , 2016)
		Oligonucleotides: F3; B3; FIP; BIP (Hamburger <i>et al.</i> , 2013)	LAMP	(Lodh <i>et al.</i> , 2017)
		77 bp fragment of internal transcribed spacer-2 (ITS2) sub-unit	qPCR/ rtPCR	(Melchers <i>et al.</i> , 2014)
	<i>S. mansoni</i>	rDNA internal transcribed spacer (ITS) region	qPCR/ rtPCR	(Sady <i>et al.</i> , 2015)
			PCR	(Sandoval <i>et al.</i> , 2006)
		28S rDNA region	PCR	(Sandoval <i>et al.</i> , 2006)
		110 bp region from highly repeated 121 bp fragment (Hamburger <i>et al.</i> , 1991)	PCR	(Enk <i>et al.</i> , 2012; Lodh <i>et al.</i> , 2013, 2014)
		Oligonucleotides: F3; B3; FIP; BIP (Hamburger <i>et al.</i> , 2013)	LAMP	(Lodh <i>et al.</i> , 2017)
		Unnamed 650 bp mitochondrial <i>S. mansoni</i> minisatellite region	LAMP	(Fernández-Soto <i>et al.</i> , 2019)
<i>S. japonicum</i>	Fragment of mitochondrial cytochrome c oxidase subunit 1 (CO1) gene	qPCR/ rtPCR	(Sady <i>et al.</i> , 2015)	
		PCR	(Kato-Hayashi <i>et al.</i> , 2015)	
Lymphatic system (adult stage/L3 larval stage) and/or circulatory system (microfilariae larval stage)	<i>W. bancrofti</i>	Unnamed tandem-specific region (Kanjanavas <i>et al.</i> , 2005)	PCR	(Ximenes <i>et al.</i> , 2014)
		188 bp fragment from <i>Ssp1</i> repeat sequence	PCR	(Lucena <i>et al.</i> , 1998)
Gastrointestinal tract (adult stage) and/or circulatory system (larval stage)	<i>S. stercoralis</i>	124 bp fragment from dispersed repeat sequence AY028262	PCR	(Lodh <i>et al.</i> , 2016; Krolewiecki <i>et al.</i> , 2018)
Central nervous system	<i>T. solium</i> (larval stage)	116 bp fragment from pTsol-9 gene	PCR	(Toribio <i>et al.</i> , 2019)

The recently developed loop-mediated isothermal amplification (LAMP) assay shows promise for future point-of-care use; DNA fragments are amplified under isothermal conditions, negating the need for thermocycling equipment essential for PCR-based assays; the assay is rapid; results can be seen with the naked-eye; multiple pathogens can be targeted and detected using one assay run; assays can be carried out by non-specialist staff; reagents can be lyophilised and initial DNA extraction steps may be less laborious (Gordon *et al.*, 2011; Zhang *et al.*, 2014; Weerakoon and McManus, 2016; Bayoumi *et al.*, 2016; Deng *et al.*, 2019). To date, LAMP has been used to successfully detect and amplify helminth DNA from other bodily samples; *S. mansoni*-derived cfDNA in urine samples taken from experimentally infected mouse models; cfDNA of *Strongyloides venezuelensis* (a rodent-infecting species) in urine samples taken from experimentally infected rat models and *S. haematobium* DNA in human urine samples (Takagi *et al.*, 2011; Fernández-Soto *et al.*, 2014, 2016, 2019; Shiraho *et al.*, 2016; Bayoumi *et al.*,

2016; Lagatie *et al.*, 2016). Despite these advantages, however, the LAMP assay does still require heat-blocks or waterbaths to heat reactions for long periods; often up to 2 hours. A reliable source of electricity is therefore still essential. Furthermore, unlike qPCR/rtPCR, LAMP assays are only semi-quantitative, meaning estimations of infection intensity are subjective and may vary between personnel; individual assays are low-throughput; amplified fragments cannot be sequenced, preventing the monitoring of genetic variation in populations over time and ambiguity exists around LAMP sensitivity when compared to alternative PCR-based approaches (Verweij and Stensvold, 2014; Zhang *et al.*, 2014; Minetti *et al.*, 2016).

To overcome many of the logistical and methodological challenges presented by PCR-based diagnostics, the point-of-care recombinase DNA-polymerase amplification (RPA) assay has also recently been developed and has been used to successfully detect and amplify *S. japonicum* and *F. hepatica* cfDNA in human stool samples, as well as *S. haematobium* DNA within

human urine samples (Piepenburg *et al.*, 2006; Sun *et al.*, 2016; Xing *et al.*, 2017; Cabada *et al.*, 2017; Li *et al.*, 2019; Rostron *et al.*, 2019). Assays to detect *S. mansoni* DNA by the use of the RPA have also recently been developed, though these have not yet been tested on clinical samples (Poulton and Webster, 2018).

Capable of detecting even trace levels of DNA, the RPA provides a promising means of reliably detecting ultra-light levels of infection in low-endemic areas (Rosser *et al.*, 2015; Lai *et al.*, 2017; Poulton and Webster, 2018; Rostron *et al.*, 2019). In addition, the assay itself offers many advantages over PCR and qPCR in terms of its methodology and potential use at the point-of-care (Aryeetey *et al.*, 2013; Lodh *et al.*, 2014; Sady *et al.*, 2015; Minetti *et al.*, 2016).

Firstly, assay reactions take place within a robust, hand-held, easily programmed, portable and battery-powered device, omitting the need for specialist technical personnel and sophisticated laboratory infrastructure. Moreover, assay results can be easily interpreted using the same device or, alternatively, *via* simple-to-use and low-cost lateral-flow immunoassay strips; both omitting the need for sophisticated and delicate readout equipment (Rosser *et al.*, 2015; Xing *et al.*, 2017; Poulton and Webster, 2018; Rostron *et al.*, 2019).

Assay reactions are also isothermal; optimal amplification occurs within 25°C – 42°C with use of the device's battery-powered heater, though testing can take place at ambient temperature in some endemic areas, or even at body temperature (Crannell *et al.*, 2014; Kersting *et al.*, 2014; Minetti *et al.*, 2016). Reaction time at reduced temperatures is, however, prolonged. Isothermal reactions not only negate the need for thermocycling equipment that may only amplify specific DNA strands based on cycle conditions within one cycle run but also allow for the detection and amplification of DNA from multiple helminth species or even other pathogens, e.g. malaria or intestinal protozoa, using only different primer combinations, within the same assay run (Crannell *et al.*, 2016). Additionally, and unlike LAMP amplicons, RPA amplicons can be sequenced, allowing the monitoring of genetic variation in populations over time (Oyola *et al.*, 2012).

Another advantage of RPA over PCR-based techniques is assay runtime; results can often be seen within 30 min of urine sample procurement as purification of total DNA from urine is not required (Kersting *et al.*, 2014; Krölov *et al.*, 2014; Rosser *et al.*, 2015; Rostron *et al.*, 2019). Therefore, sample preparation is also less laborious and more field-applicable than these alternative DNA amplification methods as only crude preparations are needed. In addition, assay reagents can be lyophilised for easy transportation and can be stored without refrigeration even in tropical ambient temperatures for several weeks (Crannell *et al.*, 2014; Oriero *et al.*, 2015).

The RPA assay is, however, much higher in cost when compared to alternative DNA amplification approaches. Estimated to cost between 4 USD\$ and 5 USD\$ per sample, the assay is currently too expensive for routine use in population-level control programmes within endemic areas (Minetti *et al.*, 2016). With further development, adaptation and uptake of the assay, however, the cost per assay sample is very likely to decrease in the near future (Rosser *et al.*, 2015).

Further drawbacks to RPA include, like LAMP, the assay's low throughput when compared to alternative PCR-based methods, though this can be resolved through manufacture of larger-capacity devices. In addition, again like LAMP results, RPA results are only semi-quantitative, making estimations of infection intensity less reliable. As such, the assay in its current form may be best suited for small sample sizes and individual test-and-treat scenarios in low-endemicity settings.

Despite these disadvantages, the RPA is an extremely promising means of rapid, straightforward and sensitive diagnosis at the point-of-care in low-endemicity settings. Further development

and validation of the RPA assay for use in diagnosing helminthiases using non-invasive urine sampling, is therefore recommended.

Novel biomarkers

Proteomic and metabolomic technologies can be used to screen bodily samples, including urine, to identify novel biomarkers that may potentially be used for diagnostic purposes. Using liquid chromatography and mass spectrometry, for example, it was recently reported that as many as 31 *Schistosoma*-derived proteins were differently abundant within the urine of patients infected with *S. haematobium* when compared to an uninfected control group and so may be used to detect active infection (Onile *et al.*, 2017). Here, it was also suggested that the presence and abundance of some transrenal host-derived proteins such as human growth/differentiation factor 15 (GDF15), upregulated in response to organ damage, may even provide a reliable means of determining disease severity and infection intensity, and so should be further evaluated.

Eosinophil cationic protein (ECP), involved in the body's immune response to foreign pathogens, has also been found to be significantly elevated in the urine of individuals infected with a variety of helminth species including *S. haematobium*, *S. mansoni*, *O. volvulus*, *W. bancrofti*, and hookworm (Tischendorf *et al.*, 1999; Tischendorf *et al.*, 2000; Klion and Nutman, 2004; Fayez *et al.*, 2010; Asuming-Brempong *et al.*, 2015). In addition to GDF15, when assessing the use of transrenal ECP as a biomarker for infection with *S. haematobium*, a positive correlation between expelled ECP and urine egg count was found, suggesting urinal ECP may too increase with infection intensity and may therefore potentially be used to assess disease severity and worm burden (Leutscher *et al.*, 2008; Leutscher *et al.*, 2000). These findings have since been replicated not only in *S. haematobium*, but also in *S. mansoni* infections (Asuming-Brempong *et al.*, 2015). More recently, ECP levels in serum samples taken from individuals infected with hookworm have also been shown to positively correlate with infection intensity (Amoani *et al.*, 2019). Repeated assessment using lesser-invasive urine samples was recommended.

Liquid chromatography has also been used in conjunction with infrared spectrophotometry to screen urine for expelled metabolites associated with helminth infections. Using this approach, it was reported that two metabolites, 2-methylbutyramide and 2-methyl-valeramide, can be detected within the urine of individuals infected with *Ascaris* (Hall and Romanova, 1990). These findings have, however, recently been contested after neither of metabolite was detected in Indonesian individuals harbouring active *Ascaris* infections (Lagatie *et al.*, 2017). In addition to liquid chromatography, nuclear magnetic resonance (NMR) spectroscopy has been used to screen urine samples taken from mice experimentally infected with *S. mansoni* for expelled metabolites (Wang *et al.*, 2004). A range of transrenal metabolites was associated with active infection and so warrant further exploration in human urine samples and in other helminth species infections.

Newly discovered transrenal biomarkers with the potential to indicate active infection, parasite burden and morbidity status may help to inform and shape future point-of-care diagnostic tools. The continued use of proteomic and metabolomic technologies for biomarker discovery is therefore strongly encouraged.

Discussion

Rapid, simple-to-use and low-cost diagnostic tools, deployable at the point-of-care and reliable in low-endemicity near-elimination

settings, are urgently needed to help facilitate the elimination of debilitating parasitic helminth diseases. Current WHO-recommended gold standard assays do not meet these criteria and typically require invasive and potentially hazardous bodily samples. Many of these criteria are, however, met by non-invasive urine-based diagnostic assays capable of detecting a range of parasitic helminth species.

Macroscopic and microscopic changes to urine are not adequately sensitive to detect urogenital schistosomiasis in light-infections, preventing their use in near-elimination settings. In addition, although anti-helminth antibodies from a range of helminth species can be detected within the urine with high sensitivity, technical, financial and logistical challenges impede the reliability and routine use of urine-antibody diagnostic assays in helminth control programmes.

POC-RDT devices capable of detecting transrenal helminth-derived antigens may offer a simple, rapid, sensitive and low-cost diagnostic format at the point-of-care in high- and medium-prevalence settings. Although not currently adequately sensitive in low-endemicity settings or at the individual-level in patients burdened with light-infections, technological advancements and protocol revisions show promise for future improvements in POC-RDT diagnostic sensitivity that may facilitate their use in low-endemicity near-elimination settings.

Targeting transrenal helminth cfDNA is extremely sensitive and specific even in low-endemicity settings. The majority of assays capable of detecting urine-cfDNA are, however, both unsuited for point-of-care use and unaffordable to most control-programmes in disease-endemic areas. The recently developed LAMP and RPA assays may offer a promising, reliable and field-deployable means of detecting helminth-derived urine-cfDNA and, through further research, development and validation is needed before their routine application in disease-endemic areas, these assays have the potential for reliable test-and-treat use in low-endemicity near-elimination settings to rapidly identify lightly infected individuals capable of maintaining disease transmission.

The majority of current literature concerned with diagnosing helminthiasis through urine sampling focuses primarily on the diagnosis of urogenital and intestinal schistosomiasis. As outlined here, many other helminth species, from a range of boldily habitats, can be detected through non-invasive urine sampling, particularly *via* targeting transrenal helminth-derived antigens and cell-free DNA. As such, the following research priorities are proposed:

- To ascertain the detectable presence of transrenal antigens and cfDNA from all of the major human-infecting parasitic helminth species.
- To determine any potential cross-reactivity of transrenal helminth-derived antigens with other antigens and/or proteins expelled in the urine and decipher how long helminth-derived cfDNA continues to be expelled within the urine after infection clearance.
- Further development and validation of rapid diagnostic tests and field-deployable assays suitable for point-of-care use and able to reliably detect trace levels of helminth-derived urine-antigens and cfDNA known to be expelled in the urine. Assay assessment should not use traditional and unreliable gold standard techniques as reference, but rather more sensitive and specific assays, such as qPCR, as reference.

Despite the high financial costs associated with developing, validating and implementing novel diagnostic tools, the programmatic and economic benefits, as well as the health benefits to those in disease-endemic areas, gained from improved diagnostics capable of detecting even trace infections at the point-of-care will very

likely outweigh any initial expenditure (Turner *et al.*, 2017). The continued investment in and development of reliable, low-cost and non-invasive urine-based diagnostic assays deployable at the point-of-care is therefore highly encouraged.

Concluding remarks

Sensitive and specific diagnosis of many major parasitic helminthiasis at the point-of-care is likely possible through non-invasive urine sampling. Though further development, assessment and validation are needed before their routine use in control programmes, low-cost and rapid assays capable of detecting transrenal helminth-derived antigens and cell-free DNA show promise for future use at the point-of-care in high-, medium- and even low-endemicity elimination settings. Ultimately, however, until these techniques are more affordable and easily implemented, less-reliable assays that require more invasive bodily samples will remain the diagnostic standard.

Acknowledgements. We wish to thank Mr Tom Pennance for his support in reading the manuscript as well as Alison Derbyshire of the Liverpool School of Tropical Medicine (LSTM) Library for essential training and extensive, valuable advice on systematic approaches to literature searching.

Financial support. None.

Conflict of interest. The authors declare that they have no competing interests.

Ethical standards. Not applicable.

References

- Adriko M, Standley CJ, Tinkitina B, Tukahebwa EM, Fenwick A, Fleming FM, Sousa-Figueiredo JC, Stothard JR and Kabatereine NB (2014) Evaluation of circulating cathodic antigen (CCA) urine-cassette assay as a survey tool for *Schistosoma mansoni* in different transmission settings within Bugiri district, Uganda. *Acta Tropica* **136**, 50–57.
- Ajibola O, Gulumbe BH, Eze AA and Obishakin E (2018) Tools for detection of Schistosomiasis in resource limited settings. *Medical Sciences* **6**, 1–12. doi: 10.3390/medsci6020039.
- Akobeng AK (2007) Understanding diagnostic tests 1: sensitivity, specificity and predictive values. *Acta Paediatrica* **96**, 333–341. doi: 10.1111/j.1651-2227.2006.00180.
- Akue JP, Eyang-Assengone E-R and Dieki R (2018) Loa loa infection detection using biomarkers: current perspectives. *Research and Reports in Tropical Medicine* **9**, 43–48.
- Amoani B, Adu B, Frempong MT, Sarkodie-Addo T, Nuvor SV, Wilson MD and Gyan B (2019) Levels of serum eosinophil cationic protein are associated with hookworm infection and intensity in endemic communities in Ghana. *PLoS ONE* **14**, e0222382.
- Aryeetey YA, Essien-Baidoo S, Larbi IA, Ahmed K, Amoah AS, Obeng BB, van Lieshout L, Yazdanbakhsh M, Boakye DA and Verweij JJ (2013) Molecular diagnosis of *Schistosoma* infections in urine samples of school children in Ghana. *The American Journal of Tropical Medicine and Hygiene* **88**, 1028–1031.
- Asuming-Brempong E, Gyan B, Amoah A, van der Puije W, Bimi L, Boakye D and Ayi I (2015) Relationship between eosinophil cationic protein and infection intensity in a schistosomiasis endemic community in Ghana. *Research and Reports in Tropical Medicine* **1**, 1–10. doi: 10.2147/RRRTM.S51713.
- Atalabi TE, Adubi TO and Lawal U (2017) Rapid mapping of urinary schistosomiasis: an appraisal of the diagnostic efficacy of some questionnaire-based indices among high school students in Katsina state, northwestern Nigeria. *PLOS Neglected Tropical Diseases* **11**, e0005518.
- Ayong LS, Tume CB, Wembe FE, Simo G, Asonganyi T, Lando G and Ngu JL (2005) Development and evaluation of an antigen detection dipstick assay for the diagnosis of human onchocerciasis. *Tropical Medicine & International Health: TM & IH* **10**, 228–233.
- Bassiouny HK, Hasab AA, El-Nimr NA, Al-Shibani LA and Al-Waleedi AA (2014) Rapid diagnosis of schistosomiasis in Yemen using a simple questionnaire and urine reagent strips. *Eastern Mediterranean Health Journal = La Revue De Sante De La Mediterranee Orientale = Al-Majallah Al-Sihhiyah Li-Sharq Al-Mutawassit* **20**, 242–249.

- Bayoumi A, Al-Refai SA and Badr MS (2016) Loop-Mediated isothermal amplification (LAMP): sensitive and rapid detection of *Schistosoma haematobium* DNA in urine samples of Egyptian suspected cases. *Journal of the Egyptian Society of Parasitology* **46**, 299–308.
- Bergquist R, Johansen MV and Utzinger J (2009) Diagnostic dilemmas in helminthology: what tools to use and when? *Trends in Parasitology* **25**, 151–156.
- Bogoch II, Andrews JR, Dadzie Ephraim RK and Utzinger J (2012) Simple questionnaire and urine reagent strips compared to microscopy for the diagnosis of *Schistosoma haematobium* in a community in northern Ghana. *Tropical Medicine & International Health: TM & IH* **17**, 1217–1221.
- Braun-Munzinger RA and Southgate BA (1992) Repeatability and reproducibility of egg counts of *Schistosoma haematobium* in urine. *Tropical medicine and parasitology: official organ of Deutsche Tropenmedizinische Gesellschaft and of Deutsche Gesellschaft für Technische Zusammenarbeit (GTZ)* **43**, 149–154.
- Cabada MM, Malaga JL, Castellanos-Gonzalez A, Bagwell KA, Naeger PA, Rogers HK, Maharsi S, Mbaka M and White AC (2017) Recombinase polymerase amplification compared to real-time polymerase chain reaction test for the detection of *Fasciola hepatica* in human stool. *The American Journal of Tropical Medicine and Hygiene* **96**, 341–346.
- Castillo Y, Rodriguez S, Garcia HH, Brandt J, Van Hul A, Silva M, Rodriguez-Hidalgo R, Portocarrero M, Melendez DP, Gonzalez AE, Gilman RH and Dorny, P and Cysticercosis Working Group in Perú (2009). Urine antigen detection for the diagnosis of human neurocysticercosis. *The American Journal of Tropical Medicine and Hygiene* **80**, 379–383.
- Chanteau S, Mouliat-Pelat JP, Glaziou P, Nguyen NL, Luquiaud P, Plichart C, Martin PM and Cartel JL (1994) Og4c3 circulating antigen: a marker of infection and adult worm burden in *Wuchereria bancrofti* filariasis. *The Journal of Infectious Diseases* **170**, 247–250.
- Chenthamarakshan V, Padigel UM, Ramaprasad P, Reddy MVR and Harinath BC (1993) Diagnostic utility of fractionated urinary filarial antigen. *Journal of Biosciences* **18**, 319–326.
- Chenthamarakshan V, Reddy MVR and Harinath BC (1996) Detection of filarial antigen by inhibition enzyme linked immunosorbent assay using fractionated *Brugia malayi* microfilarial excretory secretory antigen. *Journal of Biosciences* **21**, 27–34.
- Christensen EE, Taylor M, Zulu SG, Lillebo K, Gundersen SG, Holmen S, Kleppa E, Vennervald BJ, Ndhlovu PD and Kjetland EF (2018) Seasonal variations in *Schistosoma haematobium* egg excretion in school-age girls in rural KwaZulu-Natal Province, South Africa. *South African Medical Journal = Suid-Afrikaanse Tydskrif vir Geneeskunde* **108**, 352–355.
- Cochrane Library. (2019). *How to use the Cochrane Library*. St Albans House, 57–59. Haymarket, St. James's, London, SW1Y 4QX. Website: <https://www.cochranelibrary.com/help/how-to-use/> (Accessed 1 September 2019).
- Coelho PMZ, Siqueira LMV, Grenfell RFQ, Almeida NBF, Katz N, Almeida Á, Carneiro NFdF and Oliveira E (2016) Improvement of POC-CCA interpretation by using lyophilization of urine from patients with *Schistosoma mansoni* Low worm burden: towards an elimination of doubts about the concept of trace. *PLoS Neglected Tropical Diseases* **10**, e0004778.
- Colley DG, Bustinduy AL, Secor WE and King CH (2014) Human schistosomiasis. *The Lancet* **383**, 2253–2264.
- Corstjens PLAM, De Dood CJ, Kornelis D, Fat EMTK, Wilson RA, Kariuki TM, Nyakundi RK, Loverde PT, Abrams WR, Tanke HJ, Van Lieshout L, Deelder AM and Van Dam GJ (2014) Tools for diagnosis, monitoring and screening of *Schistosoma* infections utilizing lateral-flow based assays and upconverting phosphor labels. *Parasitology* **141**, 1841–1855.
- Corstjens PLAM, Hoekstra PT, de Dood CJ and van Dam GJ (2017) Corstjens, P. L. A. M., hoekstra, P. T., de dood, C. J. and van Dam, G. J. (2017). utilizing the ultrasensitive *Schistosoma* up-converting phosphor lateral flow circulating anodic antigen (UCP-LF CAA) assay for sample pooling-strategies. *Infectious Diseases of Poverty* **6**, 155.
- Coulibaly JT, N'Goran EK, Utzinger J, Doenhoff MJ and Dawson EM (2013) A new rapid diagnostic test for detection of anti-*Schistosoma mansoni* and anti-*Schistosoma haematobium* antibodies. *Parasites & Vectors* **6**, 29.
- Crannell ZA, Rohrman B and Richards-Kortum R (2014) Equipment-free incubation of recombinase polymerase amplification reactions using body heat. *PLoS ONE* **9**, e112146.
- Crannell Z, Castellanos-Gonzalez A, Nair G, Mejia R, White AC and Richards-Kortum R (2016) Multiplexed recombinase polymerase amplification assay to detect intestinal protozoa. *Analytical Chemistry* **88**, 1610–1616.
- Danso-Appiah A, Minton J, Boamah D, Otchere J, Asmah RH, Rodgers M, Bosompem KM, Eusebi P and De Vlas SJ (2016) Accuracy of point-of-care testing for circulatory cathodic antigen in the detection of schistosome infection: systematic review and meta-analysis. *Bulletin of the World Health Organization* **94**, 522–533A.
- de Dood CJ, Hoekstra PT, Mngara J, Kalluvya SE, van Dam GJ, Downs JA and Corstjens PLAM (2018) Refining diagnosis of *Schistosoma haematobium* infections: antigen and antibody detection in urine. *Frontiers in Immunology* **9**, 1–9. doi: 10.3389/fimmu.2018.02635.
- Deng M-H, Zhong L-Y, Kamolnetr O, Limpanont Y and Lv Z-Y (2019) Detection of helminths by loop-mediated isothermal amplification assay: a review of updated technology and future outlook. *Infectious Diseases of Poverty* **8**, 20.
- Doenhoff MJ, Chiodini PL and Hamilton JV (2004) Specific and sensitive diagnosis of schistosome infection: can it be done with antibodies? *Trends in Parasitology* **20**, 35–39.
- Drame PM, Meng Z, Bennuru S, Herrick JA, Veenstra TD and Nutman TB (2016) Identification and validation of *Loa Loa* microfilaria-specific biomarkers: a rational design approach using proteomics and novel immunoassays. *mBio* **7**, e02132–15, /mbio/7/1/e02132-15.atom.
- Eamudomkarn C, Sithithaworn P, Kamamia C, Yakovleva A, Sithithaworn J, Kaewkes S, Techasen A, Loilome W, Yongvanit P, Wangboon C, Saichua P, Itoh M and Bethony MJ (2018) Diagnostic performance of urinary IgG antibody detection: a novel approach for population screening of strongyloidiasis. *PLoS ONE* **13**, e0192598.
- Elhag SM, Abdelkareem EA, Yousif AS, Frah EA and Mohamed AB (2011) Detection of schistosomiasis antibodies in urine patients as a promising diagnostic maker. *Asian Pacific Journal of Tropical Medicine* **4**, 773–777.
- Enk MJ, Oliveira e Silva G and Rodrigues NB (2010) A salting out and resin procedure for extracting *Schistosoma mansoni* DNA from human urine samples. *BMC Research Notes* **3**, 115.
- Enk MJ, Oliveira e Silva G and Rodrigues NB (2012) Diagnostic accuracy and applicability of a PCR system for the detection of *Schistosoma mansoni* DNA in human urine samples from an endemic area. *PLoS ONE* **7**, e38947.
- Fayez S, Zaki MM, Elawady AA and El-Gebaly NSM (2010) Assessment of the Role of Serum and Urine Eosinophil Cationic Protein in Diagnosis of *Wuchereria bancrofti* Infection. **9**.
- Fernández-Soto P, Gandasegui Arahuetes J, Sánchez Hernández A, López Abán J, Vicente Santiago B and Muro A (2014) A loop-mediated isothermal amplification (LAMP) assay for early detection of *Schistosoma mansoni* in stool samples: a diagnostic approach in a murine model. *PLoS Neglected Tropical Diseases* **8**, e3126.
- Fernández-Soto P, Sánchez-Hernández A, Gandasegui J, Bajo Santos C, López-Abán J, Saugar JM, Rodríguez E, Vicente B and Muro A (2016) Strong-LAMP: a LAMP assay for Strongyloides spp. Detection in stool and urine samples. Towards the diagnosis of human strongyloidiasis starting from a rodent model. *PLoS Neglected Tropical Diseases* **10**, e0004836.
- Fernández-Soto P, Gandasegui J, Carranza Rodríguez C, Pérez-Arellano JL, Crego-Vicente B, García-Bernalt Diego J, López-Abán J, Vicente B and Muro A (2019) Detection of *Schistosoma mansoni*-derived DNA in human urine samples by loop-mediated isothermal amplification (LAMP). *PLoS ONE* **14**, e0214125.
- Garcia HH, Castillo Y, Gonzales I, Bustos JA, Saavedra H, Jacob L, Del Brutto OH, Wilkins PP, Gonzalez AE and Gilman RH and Cysticercosis Working Group in Peru (2018). Low sensitivity and frequent cross-reactions in commercially available antibody detection ELISA assays for taenia solium cysticercosis. *Tropical Medicine & International Health: TM & IH* **23**, 101–105.
- Gardon J, Gardon-Wendel N, Demanga-Ngangue N, Kamgno J, Chippaux JP and Boussinesq M (1997) Serious reactions after mass treatment of onchocerciasis with ivermectin in an area endemic for *Loa loa* infection. *Lancet (London, England)* **350**, 18–22.
- Genta RM (1988) Predictive value of an enzyme-linked immunosorbent assay (ELISA) for the serodiagnosis of strongyloidiasis. *American Journal of Clinical Pathology* **89**, 391–394.
- Google Scholar (2019) *1600 Amphitheatre Parkway*, California, USA: Mountain View. Website: <https://scholar.google.com> (Accessed 1 September 2019).
- Gordon CA, Gray DJ, Gobert GN and McManus DP (2011) DNA Amplification approaches for the diagnosis of key parasitic helminth infections of humans. *Molecular and Cellular Probes* **25**, 143–152.
- Hall A and Romanova T (1990) *Ascaris lumbricoides*: detecting its metabolites in the urine of infected people using gas-liquid chromatography. *Exp Parasitol.* **70**, 25–42.
- Hamburger J, Turetski T, Kapeller I and Deresiewicz R (1991) Highly repeated short DNA sequences in the genome of *Schistosoma mansoni*

- recognised by a species-specific probe. *Molecular and Biochemical Parasitology* **44**, 73–80. doi:10.1016/0166-6851(91)90222-R.
- Hamburger J, Abbasi I, Kariuki C, Wanjala A, Mzungu E, Mungai P, Muchiri E and King CH** (2013) Evaluation of loop-mediated isothermal amplification suitable for molecular monitoring of schistosome-infected snails in field laboratories. *The American Journal of Tropical Medicine and Hygiene* **88**, 344–351. doi: 10.4269/ajtmh.2012.12-0208.
- Hassan J, Mohammed K, Opaluwa S, Adamu T, Nataala S, Garba M, Bello M and Bunza N** (2018) Diagnostic potentials of haematuria and proteinuria in urinary schistosomiasis among school-Age children in aliero local government area, kebbi state, north-western Nigeria. *Asian Journal of Research in Medical and Pharmaceutical Sciences* **2**, 1–9.
- Hawkins KR, Cantera JL, Storey HL, Leader BT and de los Santos T** (2016) Diagnostic tests to support late-stage control programs for schistosomiasis and soil-transmitted helminthiases. *PLoS Neglected Tropical Diseases* **10**, 1–15. doi: 10.1371/journal.pntd.0004985.
- Henry D, Dessaint JP, Wandji K and Centre AC** (1987) Lymphatic filariasis: detection of circulating and urinary antigen and differences in antibody isotypes complexed with circulating antigen between symptomatic and asymptomatic subjects. *Clinical Experimental Immunology* **71**, 253–260, PMC 3280185.
- Hertz MI, Nana-Djeunga H, Kamgno J, Jelil Njouendou A, Chawa Chunda V, Wanji S, Rush A, Fischer PU, Weil GJ and Budge PJ** (2018) Identification and characterization of Loa loa antigens responsible for cross-reactivity with rapid diagnostic tests for lymphatic filariasis. *PLoS Neglected Tropical Diseases* **12**, e0006963.
- Hotez PJ, Brindley PJ, Bethony JM, King CH, Pearce EJ and Jacobson J** (2008) Helminth infections: the great neglected tropical diseases. *The Journal of Clinical Investigation* **118**, 1311–1321.
- Huijun Z, Zhengou T, Reddy MVR, Harinath BC and Piessens WF** (1987) Parasite antigens in Sera and urine of patients with Bancroftian and Brugian Filariasis detected by sandwich Elisa with monoclonal antibodies. *The American Journal of Tropical Medicine and Hygiene* **36**, 554–560.
- Ibironke O, Koukounari A, Asaolu S, Moustaki I and Shiff C** (2012) Validation of a new test for *Schistosoma haematobium* based on detection of Dra1 DNA fragments in urine: evaluation through latent class analysis. *PLoS Neglected Tropical Diseases* **6**, e1464.
- Itoh M, Kimura E, Fujimaki Y, Weerasooriya MV, Islam MZ and Qiu X-G** (2003a) Prevalence and levels of filaria-specific urinary IgG4 among children less than five years of age and the association of antibody positivity between children and their mothers. *The American Journal of Tropical Medicine and Hygiene* **68**, 465–468.
- Itoh M, Ohta N, Kanazawa T, Nakajima Y, Sho M, Minai M, Daren Z, Chen Y, He H, He Y-K and Zhong Z** (2003b) Sensitive enzyme-linked immunosorbent assay with urine samples: a tool for surveillance of schistosomiasis japonica. *The Southeast Asian Journal of Tropical Medicine and Public Health* **34**, 469–472.
- Itoh M, Wu W, Sun D, Yao L, Li Z, Islam MZ, Chen R, Zhang K, Wang F, Zhu S and Kimura E** (2007) Confirmation of elimination of lymphatic filariasis by an IgG4 enzyme-linked immunosorbent assay with urine samples in Yongjia, Zhejiang province and Gaoan, Jiangxi province, People's Republic of China. *The American Journal of Tropical Medicine and Hygiene* **77**, 330–333.
- Itoh M, Weerasooriya MV, Yahathugoda TC, Takagi H, Samarawickrema WA, Nagaoka F and Kimura E** (2011) Effects of 5 rounds of mass drug administration with diethylcarbamazine and albendazole on filaria-specific IgG4 titers in urine: 6-year follow-up study in Sri Lanka. *Parasitology International* **60**, 393–397.
- Jourdan PM, Lambertson PHL, Fenwick A and Addiss DG** (2018) Soil-transmitted helminth infections. *The Lancet* **391**, 252–265.
- Kamel M, Salah F, Demerdash Z, Maher S, Atta S, Badr A, Afifi A and El Baz H** (2019) Development of new lateral-flow immunochromatographic strip using colloidal gold and mesoporous silica nanoparticles for rapid diagnosis of active schistosomiasis. *Asian Pacific Journal of Tropical Biomedicine* **9**, 315.
- Kanjanavas P, Tan-ariya P, Khawsak P, Pakpitcharoen A, Phantana S and Chansiri K** (2005) Detection of lymphatic Wuchereria bancrofti in carriers and long-term storage blood samples using semi-nested PCR. *Molecular and Cellular Probes* **19**(3), 169–172. doi: 10.1016/j.mcp.2004.11.003.
- Kato-Hayashi N, Leonardo LR, Arevalo NL, Tagum MNB, Apin J, Agsolid LM, Chua JC, Villacorte EA, Kirinoki M, Kikuchi M, Ohmae H, Haruki K and Chigusa Y** (2015) Detection of active schistosome infection by cell-free circulating DNA of *Schistosoma japonicum* in highly endemic areas in Sorsogon Province, the Philippines. *Acta Tropica* **141**, 178–183.
- Kayuni S, Lampiao F, Makaula P, Juziwele L, Lacourse EJ, Reinhard-Rupp J, Leutscher PDC and Stothard JR** (2019) A systematic review with epidemiological update of male genital schistosomiasis (MGS): a call for integrated case management across the health system in sub-Saharan Africa. *Parasite Epidemiology and Control* **4**, e00077.
- Kemal J, Alemu S, Yimer M and Terefe G** (2015) Immunological and molecular diagnostic tests for Cestodes and metacestodes: review. *World Applied Sciences Journal* **33**, 1867–1879.
- Kersting S, Rausch V, Bier FF and von Nickisch-Roseneck M** (2014) Rapid detection of *Plasmodium falciparum* with isothermal recombinase polymerase amplification and lateral flow analysis. *Malaria Journal* **13**, 99.
- King CH and Bertsch D** (2013) Meta-analysis of urine heme dipstick diagnosis of *Schistosoma haematobium* infection, including low-prevalence and previously-treated populations. *PLoS Neglected Tropical Diseases* **7**, e2431.
- Klepac P, Metcalf CJE, McLean AR and Hampson K** (2013) Towards the endgame and beyond: complexities and challenges for the elimination of infectious diseases. *Philosophical Transactions of the Royal Society of London. Series B, Biological Sciences* **368**, 20120137.
- Klion AD and Nutman TB** (2004) The role of eosinophils in host defense against helminth parasites. *Journal of Allergy and Clinical Immunology* **113**, 30–37.
- Knopp S, Steinmann P, Hatz C, Keiser J and Utzinger J** (2012) Nematode infections: filariases. *Infectious Disease Clinics of North America* **26**, 359–381.
- Knopp S, Becker SL, Ingram KJ, Keiser J and Utzinger J** (2013) Diagnosis and treatment of schistosomiasis in children in the era of intensified control. *Expert Review of Anti-Infective Therapy* **11**, 1237–1258.
- Knopp S, Corstjens PLAM, Koukounari A, Cercamondi CI, Ame SM, Ali SM, de Dood CJ, Mohammed KA, Utzinger J, Rollinson D and van Dam GJ** (2015) Sensitivity and specificity of a urine circulating anodic antigen test for the diagnosis of *Schistosoma haematobium* in low endemic settings. *PLoS Neglected Tropical Diseases* **9**, e0003752.
- Knopp S, Ame SM, Hattendorf J, Ali SM, Khamis IS, Bakar F, Khamis MA, Person B, Kabole F and Rollinson D** (2018) Urogenital schistosomiasis elimination in Zanzibar: accuracy of urine filtration and haematuria reagent strips for diagnosis using light intensity *Schistosoma haematobium* infections. *Parasites & Vectors* **11**, 552.
- Krauth SJ, Greter H, Stete K, Coulibaly JT, Traoré SI, Ngandolo BNR, Achi LY, Zinsstag J, N'Goran EK and Utzinger J** (2015) All that is blood is not schistosomiasis: experiences with reagent strip testing for urogenital schistosomiasis with special consideration to very-low prevalence settings. *Parasites & Vectors* **8**, 584.
- Krolewiecki AJ, Koukounari A, Romano M, Caro RN, Scott AL, Fleitas P, Cimino R and Shiff CJ** (2018) Transrenal DNA-based diagnosis of *Strongyloides stercoralis* (grassi, 1879) infection: bayesian latent class modeling of test accuracy. *PLoS Neglected Tropical Diseases* **12**, e0006550.
- Krölov K, Frolova J, Tudoran O, Suhorutsenko J, Lehto T, Sibul H, Mäger I, Laanpere M, Tulp I and Langel Ü** (2014) Sensitive and rapid detection of Chlamydia trachomatis by recombinase polymerase amplification directly from urine samples. *The Journal of Molecular Diagnostics* **16**, 127–135.
- Kukula VA, MacPherson EE, Tsey IH, Stothard JR, Theobald S and Gyapong M** (2019) A major hurdle in the elimination of urogenital schistosomiasis revealed: identifying key gaps in knowledge and understanding of female genital schistosomiasis within communities and local health workers. *PLoS Neglected Tropical Diseases* **13**, e0007207.
- Lagatie O, Merino M, Batsa Debrah L, Debrah AY and Stuyver LJ** (2016) An isothermal DNA amplification method for detection of *Onchocerca volvulus* infection in skin biopsies. *Parasites & Vectors* **9**, 624.
- Lagatie O, Njunge Ediage E, Pikkemaat JA, Djuardi Y and Stuyver LJ** (2017) 2-methyl Butyramide, a previously identified urine biomarker for *Ascaris lumbricoides*, is not present in infected Indonesian individuals. *Parasites & Vectors* **10**, 629.
- Lai M-Y, Ooi C-H and Lau Y-L** (2017) Rapid detection of *Plasmodium knowlesi* by isothermal recombinase polymerase amplification assay. *The American Journal of Tropical Medicine and Hygiene* **97**, 1597–1599.
- Lamberton PHL and Jourdan PM** (2015) Human ascariasis: diagnostics update. *Current Tropical Medicine Reports* **2**, 189–200.
- Lammie PJ, Weil G, Noordin R, Kaliraj P, Steel C, Goodman D, Lakshminathan VB and Ottesen E** (2004) Recombinant antigen-based

- antibody assays for the diagnosis and surveillance of lymphatic filariasis—a multicenter trial. *Filaria Journal* 3, 9.
- Lazcka O, Del Campo FJ and Muñoz FX** (2007) Pathogen detection: a perspective of traditional methods and biosensors. *Biosensors & Bioelectronics* 22, 1205–1217.
- Le L and Hsieh MH** (2017) Diagnosing urogenital schistosomiasis: dealing with diminishing returns. *Trends in Parasitology* 33, 378–387.
- Lengeler C, Utzinger J and Tanner M** (2002a) Questionnaires for rapid screening of schistosomiasis in sub-Saharan Africa. *Bulletin of the World Health Organization* 80, 235–242.
- Lengeler C, Utzinger J and Tanner M** (2002b) Screening for schistosomiasis with questionnaires. *Trends in Parasitology* 18, 375–377.
- Leutscher PDC, Reimert CM, Vennervald BJ, Ravaoalimalala VE, Ramarakoto CE, Serieye J, Raobelison A, Rasendramino M, Christensen NO and Esterre P** (2000) Morbidity assessment in urinary schistosomiasis infection through ultrasonography and measurement of eosinophil cationic protein (ECP) in urine. *Tropical Medicine and International Health* 5, 88–93.
- Leutscher PDC, van Dam GTJ, Reimert CM, Ramarakoto CE, Deelder AM and Ørnberg N** (2008) Eosinophil Cationic Protein, Soluble Egg Antigen, Circulating Anodic Antigen, and Egg Excretion in Male Urogenital Schistosomiasis. *The American Journal of Tropical Medicine and Hygiene* 79, 422–426. doi: 10.4269/ajtmh.2008.79.422.
- Li J, Macdonald J and von Stetten F** (2019) Review: a comprehensive summary of a decade development of the recombinase polymerase amplification. *The Analyst* 144, 31–67.
- Lodh N, Mwansa JCL, Mutengo MM and Shiff CJ** (2013) Diagnosis of *Schistosoma mansoni* without the stool: comparison of three diagnostic tests to detect *Schistosoma* [corrected] *mansoni* infection from filtered urine in Zambia. *The American Journal of Tropical Medicine and Hygiene* 89, 46–50.
- Lodh N, Naples JM, Bosompem KM, Quartey J and Shiff CJ** (2014) Detection of parasite-specific DNA in urine sediment obtained by filtration differentiates between single and mixed infections of *Schistosoma mansoni* and *S. haematobium* from endemic areas in Ghana. *PLoS ONE* 9, e91144.
- Lodh N, Caro R, Sofer S, Scott A, Krolewiecki A and Shiff C** (2016) Diagnosis of *Strongyloides stercoralis*: detection of parasite-derived DNA in urine. *Acta Tropica* 163, 9–13.
- Lodh N, Mikita K, Bosompem KM, Anyan WK, Quartey JK, Otchere J and Shiff CJ** (2017) Point of care diagnosis of multiple schistosome parasites: species-specific DNA detection in urine by loop-mediated isothermal amplification (LAMP). *Acta Tropica* 173, 125–129.
- Lucena WA, Dhalia R, Abath FG, Nicolas L, Regis LN and Furtado AF** (1998) Diagnosis of *Wuchereria bancrofti* infection by the polymerase chain reaction using urine and day blood samples from amicrofilaraemic patients. *Transactions of the Royal Society of Tropical Medicine and Hygiene* 92, 290–293.
- Lustigman S, Prichard RK, Gazzinelli A, Grant WN, Boatin BA, McCarthy JS and Basáñez M-G** (2012) A research agenda for helminth diseases of humans: the problem of helminthiasis. *PLoS Neglected Tropical Diseases* 6, e1582.
- McCarthy JS, Lustigman S, Yang G-J, Barakat RM, García HH, Sripa B, Willingham AL, Prichard RK and Basáñez M-G** (2012) A research agenda for helminth diseases of humans: diagnostics for control and elimination programmes. *PLoS Neglected Tropical Diseases* 6, e1601.
- Melchers NVSV, van Dam GJ, Shaproski D, Kahama AI, Brienen EAT, Vennervald BJ and van Lieshout L** (2014) Diagnostic performance of *Schistosoma* real-time PCR in urine samples from Kenyan children infected with *Schistosoma haematobium*: day-to-day variation and follow-up after praziquantel treatment. *PLoS Neglected Tropical Diseases* 8, e2807.
- Minetti C, Lacourse EJ, Reimer L and Stothard JR** (2016) Focusing nucleic acid-based molecular diagnostics and xenomonitoring approaches for human helminthiasis amenable to preventive chemotherapy. *Parasitology Open* 2, e16.
- Montresor, A, Crompton, DWT, Gyorkos, TW, Savioli, L and Organization, WH** (2002) *Helminth Control in School-Age Children: A Guide for Managers of Control Programmes*. Second edition. Geneva, Switzerland: World Health Organization.
- Musa NY and Dadah AJ** (2018) Comparing the sensitivity of microscopy to diagnostic strip in the survey for urinary schistosomiasis. *Bioprocess Engineering* 2, 14.
- Mutapi F, Maizels R, Fenwick A and Woolhouse M** (2017) Human schistosomiasis in the post mass drug administration era. *The Lancet Infectious Diseases* 17, e42–e48.
- Mwape KE, Praet N, Benitez-Ortiz W, Muma JB, Zulu G, Celi-Erazo M, Phiri IK, Rodriguez-Hidalgo R, Dorny P and Gabriël S** (2011) Field evaluation of urine antigen detection for diagnosis of *Taenia solium* cysticercosis. *Transactions of the Royal Society of Tropical Medicine and Hygiene* 105, 574–578. doi: 10.1016/j.trstmh.2011.05.010.
- Nagaoka F, Itoh M, Samad MS, Takagi H, Weerasooriya MV, Yahathugoda TC, Hossain M, Moji K and Kimura E** (2013) Visual detection of filaria-specific IgG4 in urine using red-colored high density latex beads. *Parasitology International* 62, 32–35.
- National Center for Biotechnology Information** (2019) *Using PubMed*. U.S. National Library of Medicine. 8600 Rockville Pike, Bethesda MD, 20894. USA. Website: <https://www.ncbi.nlm.nih.gov/pubmed/> (Accessed 1 September 2019).
- Ochodo EA, Gopalakrishna G, Spek B, Reitsma JB, van Lieshout L, Polman K, Lamberton P, Bossuyt PMM and Leeflang MMG** (2015) Circulating antigen tests and urine reagent strips for diagnosis of active schistosomiasis in endemic areas. *The Cochrane Database of Systematic Reviews* 3, CD009579. doi: 10.1002/14651858.CD009579.pub2.
- Okeke OC and Ubachukwu PO** (2014) Performance of three rapid screening methods in the detection of *Schistosoma haematobium* infection in school-age children in southeastern Nigeria. *Pathogens and Global Health* 108, 111–117.
- Onile OS, Calder B, Soares NC, Anumudu CI and Blackburn JM** (2017) Quantitative label-free proteomic analysis of human urine to identify novel candidate protein biomarkers for schistosomiasis. *PLoS Neglected Tropical Diseases* 11, e0006045.
- Oriero EC, Jacobs J, Van Geertruyden J-P, Nwakanma D and D'Alessandro U** (2015) Molecular-based isothermal tests for field diagnosis of malaria and their potential contribution to malaria elimination. *Journal of Antimicrobial Chemotherapy* 70, 2–13.
- Oyola SO, Otto TD, Gu Y, Maslen G, Manske M, Campino S, Turner DJ, MacInnis B, Kwiatkowski DP, Swerdlow HP and Quail MA** (2012) Optimizing illumina next-generation sequencing library preparation for extremely at-biased genomes. *BMC Genomics* 13, 1.
- Paredes A, Sáenz P, Marzal MW, Orrego MA, Castillo Y, Rivera A, Mahanty S, Guerra-Giraldez C, García HH and Nash TE** (2016) Anti-*Taenia solium* monoclonal antibodies for the detection of parasite antigens in body fluids from patients with neurocysticercosis. *Experimental Parasitology* 166, 37–43. doi: 10.1016/j.exppara.2016.03.025.
- Peralta JM and Cavalcanti MG** (2018) Is POC-CCA a truly reliable test for schistosomiasis diagnosis in low endemic areas? The trace results controversy. *PLoS Neglected Tropical Diseases* 12, e0006813.
- Peters PA, Warren KS and Mahmoud AA** (1976) Rapid, accurate quantification of schistosome eggs *Via* Nuclepore filters. *The Journal of Parasitology* 62, 154–155.
- Phuphisut O, Yoonuan T, Sanguankiat S, Chaisiri K, Maipanich W, Pubampen S, Komalamisra C and Adisakwattana P** (2014) *Ascaris lumbricoides*, trichuris trichiuris, necator americanus, in fecal samples. *Southeast Asian Journal of Tropical Medicine and Public Health* 45, 9.
- Piepenburg O, Williams CH, Stemple DL and Armes NA** (2006) DNA Detection using recombination proteins. *PLoS Biology* 4, e204.
- Poulton K and Webster B** (2018) Development of a lateral flow recombinase polymerase assay for the diagnosis of *Schistosoma mansoni* infections. *Analytical Biochemistry* 546, 65–71.
- Ramaprasad P, Prasad GB and Harinath BC** (1988) Microfilaraemia, filarial antibody, antigen and immune complex levels in human filariasis before, during and after DEC therapy. A two-year follow-up. *Acta Tropica* 45, 245–255.
- Rattanaxay P, Gunawardena NK, Itoh M, Fujimaki Y, Anantaphruti MT, Weerasooriya MV, Kimura E, Tesana S and Qiu G** (2001) Sensitive and specific enzyme-linked immunosorbent assay for the diagnosis of *Wuchereria bancrofti* infection in urine samples. *The American Journal of Tropical Medicine and Hygiene* 65, 362–365.
- Rebollo MP and Bockarie MJ** (2014) Shrinking the lymphatic filariasis map: update on diagnostic tools for mapping and transmission monitoring. *Parasitology* 141, 1912–1917.
- Robinson E, Picon D, Sturrock HJ, Sabasio A, Lado M, Kolaczinski J and Brooker S** (2009) The performance of haematuria reagent strips for the rapid mapping of urinary schistosomiasis: field experience from southern Sudan. *Tropical Medicine & International Health* 14, 1484–1487.

- Rollinson D, Klinger EV, Mgeni AF, Khamis IS and Stothard JR (2005) Urinary schistosomiasis on Zanzibar: application of two novel assays for the detection of excreted albumin and haemoglobin in urine. *Journal of Helminthology* **79**, 199–206.
- Rollinson D, Knopp S, Levitz S, Stothard JR, Tchuem Tchuente L-A, Garba A, Mohammed KA, Schur N, Person B, Colley DG and Utzinger J (2013) Time to set the agenda for schistosomiasis elimination. *Acta Tropica* **128**, 423–440.
- Rosser A, Rollinson D, Forrest M and Webster BL (2015) Isothermal recombinase polymerase amplification (RPA) of *Schistosoma haematobium* DNA and oligochromatographic lateral flow detection. *Parasites & Vectors* **8**, 446.
- Rostron P, Pennance T, Bakar F, Rollinson D, Knopp S, Allan F, Kabole F, Ali SM, Ame SM and Webster BL (2019) Development of a recombinase polymerase amplification (RPA) fluorescence assay for the detection of *Schistosoma haematobium*. *Parasites & Vectors* **12**, 1–7. doi: 10.1186/s13071-019-3755-6.
- Sady H, Al-Mekhlafi HM, Ngui R, Atroosh WM, Al-Delaimy AK, Nasr NA, Dawaki S, Abdulsalam AM, Ithoi I, Lim YAL, Chua KH and Surin J (2015) Detection of *Schistosoma mansoni* and *Schistosoma haematobium* by real-time PCR with high resolution melting analysis. *International Journal of Molecular Sciences* **16**, 16085–16103.
- Samad MS, Itoh M, Moji K, Hossain M, Mondal D, Alam MS and Kimura E (2013) Enzyme-linked immunosorbent assay for the diagnosis of *Wuchereria bancrofti* infection using urine samples and its application in Bangladesh. *Parasitology International* **62**, 564–567.
- Sandoval N, Siles-Lucas M, Pérez-Arellano JL, Carranza C, Puente S, López-Abán J and Muro A (2006) A new PCR-based approach for the specific amplification of DNA from different *Schistosoma* species applicable to human urine samples. *Parasitology* **133**, 581–587.
- Sawangsoda P, Sithithaworn J, Tesana S, Pinlaor S, Boonmars T, Mairiang E, Yongvanit P, Duengngai K and Sithithaworn P (2012) Diagnostic values of parasite-specific antibody detections in saliva and urine in comparison with serum in opisthorchiasis. *Parasitology International* **61**, 196–202.
- Sheele JM, Kihara JH, Baddorf S, Byrne J and Ravi B (2013) Evaluation of a novel rapid diagnostic test for *Schistosoma haematobium* based on the detection of human immunoglobulins bound to filtered *Schistosoma haematobium* eggs. *Tropical Medicine & International Health: TM & IH* **18**, 477–484.
- Shiff C, Garba A, Phillips AE, Lamine SM and Ibronek OA (2011) Diagnosis of *Schistosoma haematobium* by detection of specific DNA fragments from filtered urine samples. *The American Journal of Tropical Medicine and Hygiene* **84**, 998–1001.
- Shiraho EA, Eric AL, Mwangi IN, Maina GM, Kinuthia JM, Mutuku MW, Mugambi RM, Mwandji JM and Mkoji GM (2016) Development of a loop mediated isothermal amplification for diagnosis of *Ascaris lumbricoides* in fecal samples. *Journal of Parasitology Research* **2016**, 1–7.
- Song HB, Kim J, Jin Y, Lee JS, Jeoung HG, Lee YH, Saeed AAW and Hong S-T (2018) Comparison of ELISA and urine microscopy for diagnosis of *Schistosoma haematobium* infection. *Journal of Korean Medical Science* **33**, 1–9. doi: 10.3346/jkms.2018.33.e238.
- Sousa MS, van Dam GJ, Pinheiro MCC, de Dood CJ, Peralta JM, Peralta RHS, de Daher EF, Corstjens PLAM and Bezerra FSM (2019) Performance of an ultra-sensitive assay targeting the circulating anodic antigen (CAA) for detection of *Schistosoma mansoni* infection in a Low endemic area in Brazil. *Frontiers in Immunology* **10**, 682.
- Sousa-Figueiredo JC, Basáñez M-G, Khamis IS, Garba A, Rollinson D and Stothard JR (2009) Measuring morbidity associated with urinary schistosomiasis: assessing levels of excreted urine albumin and urinary tract pathologies. *PLoS Neglected Tropical Diseases* **3**, e526.
- Sousa-Figueiredo JC, Betson M, Kabatereine NB and Stothard JR (2013) The urine circulating cathodic antigen (CCA) dipstick: a valid substitute for microscopy for mapping and point-Of-care diagnosis of intestinal schistosomiasis. *PLoS Neglected Tropical Diseases* **7**, e2008.
- Steel C, Golden A, Kubofcik J, LaRue N, de los Santos T, Domingo GJ and Nutman TB (2013) Rapid *Wuchereria bancrofti*-specific antigen Wb123-based IgG4 immunoassays as tools for surveillance following mass drug administration programs on lymphatic filariasis. *Clinical and Vaccine Immunology* **20**, 1155–1161.
- Stete K, Krauth SJ, Coulibaly JT, Knopp S, Hattendorf J, Müller I, Lohourignon LK, Kern WV, N'Goran EK and Utzinger J (2012) Dynamics of *Schistosoma haematobium* egg output and associated infection parameters following treatment with praziquantel in school-aged children. *Parasites & Vectors* **5**, 298.
- Stothard JR, Kabatereine NB, Tukahebwa EM, Kazibwe F, Rollinson D, Mathieson W, Webster JP and Fenwick A (2006) Use of circulating cathodic antigen (CCA) dipsticks for detection of intestinal and urinary schistosomiasis. *Acta Tropica* **97**, 219–228.
- Stothard JR, Stanton MC, Bustinduy AL, Sousa-Figueiredo JC, Van Dam GJ, Betson M, Waterhouse D, Ward S, Allan F, Hassan AA, Al-Helal MA, Memish ZA and Rollinson D (2014) Diagnostics for schistosomiasis in Africa and Arabia: a review of present options in control and future needs for elimination. *Parasitology* **141**, 1947–1961.
- Sun K, Xing W, Yu X, Fu W, Wang Y, Zou M, Luo Z and Xu D (2016) Recombinase polymerase amplification combined with a lateral flow dipstick for rapid and visual detection of *Schistosoma japonicum*. *Parasites & Vectors* **9**, 476.
- Takagi H, Itoh M, Kasai S, Yahathugoda TC, Weerasooriya MV and Kimura E (2011) Development of loop-mediated isothermal amplification method for detecting *Wuchereria bancrofti* DNA in human blood and vector mosquitoes. *Parasitology International* **60**, 493–497.
- Takagi H, Yahathugoda TC, Tojo B, Rathnapala UL, Nagaoka F, Weerasooriya MV and Itoh M (2019) Surveillance of *Wuchereria bancrofti* infection by anti-filarial IgG4 in urine among schoolchildren and molecular xenomonitoring in Sri Lanka: a post mass drug administration study. *Tropical Medicine and Health* **47**, 39.
- Tchuem Tchuente LA (2011) Control of soil-transmitted helminths in sub-Saharan Africa: diagnosis, drug efficacy concerns and challenges. *Acta Tropica* **120**, S4–S11.
- Tesana S, Srisawangwong T, Sithithaworn P, Itoh M and Phumchaiyothin R (2007) The ELISA-based detection of anti-*Opisthorchis viverrini* IgG and IgG4 in samples of human urine and serum from an endemic area of north-eastern Thailand. *Annals of Tropical Medicine and Parasitology* **101**, 585–591.
- Tischendorf FW, Brattig NW, Burchard GD, Kubica T, Kreuzpainer G and Lintzel M (1999) Eosinophils, eosinophil cationic protein and eosinophil-derived neurotoxin in serum and urine of patients with onchocerciasis coinfecting with intestinal nematodes and in urinary schistosomiasis. *Acta Tropica* **72**, 157–173.
- Tischendorf FW, Brattig NW, Lintzel M, Buttner DW, Burchard GD, Bork K and Muller M (2000) Eosinophil granule proteins in serum and urine of patients with helminth infections and atopic dermatitis. *Tropical Medicine and International Health* **5**, 898–905.
- Toribio, L., Romano, M., Scott, A. L., Gonzales, I., Saavedra, H., Garcia, H. H. and Shiff, C. and Peru, for the C. W. G. (2019). Detection of *Taenia solium* DNA in the urine of neurocysticercosis patients. *The American Journal of Tropical Medicine and Hygiene* **100**, 327–329.
- Turner HC, Bettis AA, Dunn JC, Whittom JM, Hollingsworth TD, Fleming FM and Anderson RM (2017) Economic considerations for moving beyond the kato-katz technique for diagnosing intestinal parasites as we move towards elimination. *Trends in Parasitology* **33**, 435–443.
- Utzinger J, Becker SL, van Lieshout L, van Dam GJ and Knopp S (2015) New diagnostic tools in schistosomiasis. *Clinical Microbiology and Infection* **21**, 529–542.
- Utzinger J, Greter H, Ngandolo BNR, Krauth SJ, Alfaroukh IO and Zinsstag J (2016) Validation of a point-of-care circulating cathodic antigen urine cassette test for *Schistosoma mansoni* diagnosis in the sahel, and potential cross-reaction in pregnancy. *The American Journal of Tropical Medicine and Hygiene* **94**, 361–364.
- van Dam GJ, Claas FH, Yazdanbakhsh M, Kruijze YC, van Keulen AC, Ferreira ST, Rotmans JP and Deelder AM (1996) *Schistosoma mansoni* excretory circulating cathodic antigen shares Lewis-x epitopes with a human granulocyte surface antigen and evokes host antibodies mediating complement-dependent lysis of granulocytes. *Blood* **88**, 4246–4251.
- van Dam GJ, Wichers JH, Ferreira TME, Ghati D, van Amerongen A and Deelder AM (2004) Diagnosis of schistosomiasis by reagent strip test for detection of circulating cathodic antigen. *Journal of Clinical Microbiology* **42**, 5458–5461.
- van Dam GJ, Xu J, Bergquist R, de Dood CJ, Utzinger J, Qin Z-Q, Guan W, Feng T, Yu X-L, Zhou J, Zheng M, Zhou X-N and Corstjens PLAM (2015a) An ultra-sensitive assay targeting the circulating anodic antigen for the diagnosis of *Schistosoma japonicum* in a low-endemic area, People's Republic of China. *Acta Tropica* **141**, 190–197.

- van Dam GJ, Odermatt P, Acosta L, Bergquist R, de Dood CJ, Kornelis D, Muth S, Utzinger J and Corstjens PLAM (2015b) Evaluation of banked urine samples for the detection of circulating anodic and cathodic antigens in *Schistosoma mekongi* and *S. japonicum* infections: a proof-of-concept study. *Acta Tropica* **141**, 198–203.
- van Grootveld R, van Dam GJ, de Dood C, de Vries JJC, Visser LG, Corstjens PLAM and van Lieshout L (2018) Improved diagnosis of active *Schistosoma* infection in travellers and migrants using the ultra-sensitive in-house lateral flow test for detection of circulating anodic antigen (CAA) in serum. *European Journal of Clinical Microbiology & Infectious Diseases: Official Publication of the European Society of Clinical Microbiology* **37**, 1709–1716.
- Verweij JJ and Stensvold CR (2014) Molecular testing for clinical diagnosis and epidemiological investigations of intestinal parasitic infections. *Clinical Microbiology Reviews* **27**, 371–418.
- Vlaminck J, Fischer PU and Weil GJ (2015) Diagnostic tools for onchocerciasis elimination programs. *Trends in Parasitology* **31**, 571–582.
- Vlaminck J, Supali T, Geldhof P, Hokke CH, Fischer PU and Weil GJ (2016) Community rates of IgG4 antibodies to *Ascaris* haemoglobin reflect changes in community Egg loads following mass drug administration. *PLoS Neglected Tropical Diseases* **10**, e0004532.
- Vlaminck J, Lagatie O, Verheyen A, Dana D, Van Dorst B, Mekonnen Z, Levecke B and Stuyver LJ (2019) Patent infections with soil-transmitted helminths and *Schistosoma mansoni* are not associated with increased prevalence of antibodies to the *Onchocerca volvulus* peptide epitopes OvMP-1 and OvMP-23. *Parasites & Vectors* **12**, 63.
- Vonghachack Y, Sayasone S, Khieu V, Bergquist R, van Dam GJ, Hoekstra PT, Corstjens PLAM, Nickel B, Marti H, Utzinger J, Muth S and Odermatt P (2017) Comparison of novel and standard diagnostic tools for the detection of *Schistosoma mekongi* infection in Lao people's democratic republic and Cambodia. *Infectious Diseases of Poverty* **6**, 127.
- Wang Y, Holmes E, Nicholson JK, Cloarec O, Chollet J, Tanner M, Singer BH and Utzinger J (2004) Metabonomic investigations in mice infected with *Schistosoma mansoni*: an approach for biomarker identification. *Proceedings of the National Academy of Sciences* **101**, 12676–12681.
- Web of Science (2019) Friars House, Blackfriars Road, London. SE1 8EZ. Website: <https://apps.webofknowledge.com> (Accessed 1 September 2019).
- Weerakoon KG and McManus DP (2016) Cell-Free DNA as a diagnostic tool for human parasitic infections. *Trends in Parasitology* **32**, 378–391.
- Weerakoon KGAD, Gobert GN, Cai P and McManus DP (2015) Advances in the diagnosis of human schistosomiasis. *Clinical Microbiology Reviews* **28**, 939–967.
- Weerakoon K, Gordon C and McManus D (2018) DNA Diagnostics for schistosomiasis control. *Tropical Medicine and Infectious Disease* **3**, 81.
- Weerasooriya M, Itoh M, Islam M, Aoki Y, Samarawickrema W and Kimura E (2008) Presence and gradual disappearance of filaria-specific urinary IgG4 in babies born to antibody-positive mothers: a 2-year follow-up study. *Parasitology International* **57**, 386–389.
- Weil GJ, Kumar H, Santhanam S, Sethumadhavan KVP and Jain DC (1986) Detection of circulating parasite antigen in Bancroftian Filariasis by counter-immunoelectrophoresis. *The American Journal of Tropical Medicine and Hygiene* **35**, 565–570.
- Weil GJ, Steel C, Liftis F, Li BW, Mearns G, Lobos E and Nutman TB (2000) A rapid-format antibody card test for diagnosis of onchocerciasis. *The Journal of Infectious Diseases* **182**, 1796–1799.
- Werkman M, Wright JE, Truscott JE, Easton AV, Oliveira RG, Toor J, Ower A, Ásbjörnsdóttir KH, Means AR, Farrell SH, Watson JL and Anderson RM (2018) Testing for soil-transmitted helminth transmission elimination: analysing the impact of the sensitivity of different diagnostic tools. *PLoS Neglected Tropical Diseases* **12**, e0006114.
- Worasith C, Kamamia C, Yakovleva A, Duengngai K, Wangboon C, Sithithaworn J, Watwiengkam N, Namwat N, Techasen A, Loilome W, Yongvanit P, Loukas A, Sithithaworn P and Bethony JM (2015) Advances in the diagnosis of human opisthorchiasis: development of *Opisthorchis viverrini* antigen detection in urine. *PLoS Neglected Tropical Diseases* **9**, e0004157.
- World Health Organisation (2012). *Research Priorities for Helminth Infections*. WHO. Technical Report Series No. 972. Geneva, Switzerland: World Health Organization.
- World Health Organization (2013). *Schistosomiasis: Progress Report 2001–2011 and Strategic Plan 2012–2020*. Geneva, Switzerland: World Health Organization.
- Ximenes C, Brandão E, Oliveira P, Rocha A, Rego T, Medeiros R, Aguiar-Santos A, Ferraz J, Reis C, Araujo P, Carvalho L and Melo FL (2014) Detection of *Wuchereria bancrofti* DNA in paired serum and urine samples using polymerase chain reaction-based systems. *Memórias do Instituto Oswaldo Cruz* **109**, 978–983.
- Xing W, Yu X, Feng J, Sun K, Fu W, Wang Y, Zou M, Xia W, Luo Z, He H, Li Y and Xu D (2017) Field evaluation of a recombinase polymerase amplification assay for the diagnosis of *Schistosoma japonicum* infection in human province of China. *BMC Infectious Diseases* **17**, 164.
- Zhang X, Lowe SB and Gooding JJ (2014) Brief review of monitoring methods for loop-mediated isothermal amplification (LAMP). *Biosensors and Bioelectronics* **61**, 491–499.

Appendix

		Infected Individuals	Uninfected Individuals	
Diagnostic Outcome	Positive	True Positive (A)	False Positive (B)	Positive Predictive Value (PPV): The probability that a positive result accurately indicates the presence of infection $\{A/(A+B)\}$
	Negative	False Negative (C)	True Negative (D)	Negative Predictive Value (NPV): The probability that a negative result accurately indicates the absence of infection $\{D/(C+D)\}$
		<i>Total number infected individuals</i> (A+C)	<i>Total number uninfected individuals</i> (B+D)	
		Sensitivity: Proportion of infected individuals who are correctly identified as such $\{A/(A+C)\}$	Specificity: Proportion of uninfected individuals who are correctly identified as such $\{D/(B+D)\}$	

Fig. A1. Defining sensitivity, specificity and predictive values (Akobeng, 2007; Bergquist et al., 2009).